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Vitamin E is a group of naturally occurring fat soluble compounds which consists 
of eight distinct forms of tocopherols and tocotrienols. Although a well-defined 
physiological function of vitamin E is as an antioxidant, beneficial effects of individual 
vitamin E compounds on chronic human diseases such as cancer need to be better 
understood. Studies in this dissertation investigated potential application of -tocopherol 
(-T), -tocotrienol (-T3) or synthetic derivatives of tocotrienols as anticancer agents in 
comparison to -tocopherol (-T), its redox-silent acetic acid derivative (-TEA) or -
tocotrienol (-T3). Redox-silent derivatives of - and -T3; namely -T3EA and -T3EA 
exhibited potent anti-proliferative and proapoptotic activities in a murine mammary 
 vii 
cancer cell line as well as in human breast cancer cell lines. Moreover, studies using 
human vascular endothelial cells in cell culture showed that the tocotrienol derivatives 
exhibited strong antiangiogenic activities which were markedly improved over those of 
the parent compounds. An antitumor efficacy study using the 66cl-4-GFP syngeneic 
mouse mammary tumor model showed that each tocotrienol derivative, when delivered in 
the  diet, significantly suppressed mammary tumor growth; however serum and tissue 
concentrations of these novel compounds were lower than those of -TEA, suggesting 
that the next generation of vitamin E derivatives will need to be modified to improve 
bioavailability. On the other hand, some natural-source vitamin E forms, especially -
forms, display anticancer activities without any chemical modification in both in vitro 
cell culture studies and in vivo animal models. Dietary delivery of -T3 suppressed tumor 
growth in a syngeneic implantation mouse mammary cancer model by inhibiting cell 
proliferation and inducing apoptosis. Cell culture studies using human breast cancer cells 
showed that -T3 triggered apoptosis by inducing endoplasmic reticulum (ER)-stress 
mediated by acid sphingomyelinase (ASMase) action. Activation of stress-activated 
mitogen-activated protein kinases (MAPKs), JNK and p38, was associated with -T3-
induced ER stress followed by upregulation of extrinsic death receptor-5 (DR5) 
expression in a CHOP transcription factor dependent manner. -T also triggered extrinsic 
apoptosis signaling by increasing DR5 mRNA, protein and cell surface expression levels 
followed by mitochondria-dependent apoptotic signaling. In agreement with in vitro 
studies, -T delivered in the diet suppressed the tumor growth of MDA-MB-231-GFP 
 viii 
human breast cancer cells in a xenograft model but the antitumor activity of -T was 
hampered by co-administration of -T. The preferential tissue retention of -T over -T 
could be overcome by use of sesamin, a dietary source of human cytochrome P450 
inhibitor. Based on data presented, -T and -T3 show preclinical potential for cancer 
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Chapter 1. Introduction 
1.1. An overview of natural vitamin E  
1.1.1. Structures and biological functions of natural vitamin E 
     Vitamin E refers a group of fat-soluble natural compounds that share a chromanol 
ring and an aliphatic side chain. Based on the degree of saturation of the side chain, 
vitamin E is divided into two subgroups called tocopherols and tocotrienols. Each 
subgroup includes -, -, γ- and -forms based on the number and location of methyl 
groups on the chroman head (Figure 1.1). Both subgroups are further diversified by 
stereoisomers: tocotrienols have one chiral center at the C2 position on the chroman head, 
whereas tocopherols have the C2 chiral center plus two more at the 4 and 8 positions on 
the phytyl tail. All naturally existing vitamin E forms have only R configurations. 
Although different forms of natural vitamin E exist, the term vitamin E is most frequently 
used to refer to R,R,R--tocopherol (-T), the vitamin E form preferentially retained in 
humans (1). Commercially available vitamin E supplements may contain naturally 
isolated -T or synthetic forms or derivatives of -T. Based on clinical reports regarding 
vitamin E supplementation, vitamin E is associated with decreased risk of chronic 
diseases such as cardiovascular diseases, atherosclerotic progression, and 
neurodegenerative diseases (2). Although a well-defined physiological function of 
vitamin E is as a fat-soluble antioxidant, various forms of vitamin E have been reported 
to possess unique biological properties such as anti-inflammatory, anti-thrombotic and 
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anticancer properties (3, 4). In this regard, tocotrienols have gained attention due to 
distinctive functions not shared by -T, such as neuroprotective, anticancer, and 
cholesterol-lowering activities (4). Another unique property of tocotrienols is the 
inhibition of angiogenesis which is believed to be a major therapeutic target for various 
human disorders including cancer, diabetic retinopathy, and rheumatoid arthritis (5, 6). 
Therefore, a better cellular and mechanistic level understanding of the various forms of 




Figure 1.1. Structure of tocopherols and tocotrienols. Naturally occurring tocopherols 
contain R-configurations at the C2 position of the chromanol ring, and C4 and C8 position 
of the phytyl tail, whereas tocotrienols have a R-configuration at the C2 position of the 








































1.1.2. Absorption and metabolism of vitamin E 
The absorption of vitamin E after dietary ingestion is dependent on fat absorption 
processes (7). Ingested vitamin E is emulsified and mixed into micelles in the small 
intestine with the aid of bile acids, pancreatic lipases and esterases. The micelles are then 
transported into the intestinal enterocytes and transferred to the lymphatic fluids in 
chylomicrons which are delivered to other lipoproteins and tissues (7). In the liver, 
tocopherol transfer protein (TTP) discriminates between different forms of vitamin E for 
enrichment of -T into nascent very low density lipoprotein (VLDL) which is 
subsequently transformed to low-density lipoprotein (LDL), the major -T carrier in 
blood (7). Studies in TTP deficient patients suggest that -TTP is required for normal -
T absorption and transportation (8). The other vitamin E compounds have lower affinity 
for TTP and are selectively metabolized in the liver resulting lower circulating and tissue 
levels (7). Interestingly, animal studies using TTP-deficient mice fed tocotrienols suggest 
that tocotrienols can be distributed into vital organs via TTP-independent pathway(s) and 
eliminate -T deficient symptoms, such as neurological disorders and female infertility 
(9).  
Elimination of absorbed vitamin E involves -hydroxylation of the phytyl side chain by 
cytochrome P450 enzyme-dependent processes followed by several steps of -oxidation 
(8). Tocotrienols and -T have been shown to activate pregnane X-receptor, a nuclear 
receptor that induces gene expression of drug metabolizing enzymes such as CYP3A4 
4 
 
(10).  Indeed, CYP3A4 and CYP4F2 are known to be the major P450 enzymes that are 
involved in vitamin E metabolism (8), which implies that the elimination of vitamin E is 
tightly regulated after vitamin E ingestion to prevent toxic accumulation. Carboxyethyl-
hydroxychroman (CEHC) is the major metabolite of all vitamin E compounds and 
excreted largely in the urine (Figure 1.2).  
 
 
Figure 1.2. Scheme of vitamin E metabolic process to form metabolic products, 2-(2-
carboxyethyl)-6-hydroxychromans (CEHCs) through CYP-mediated -hydroxylation 





























1.1.3. Anticancer activities of natural vitamin E 
Major efforts have been made to demonstrate a chemopreventive role for vitamin E in 
cancer; however, neither preclinical nor clinical studies support a beneficial effect of -T, 
-T derivative (R,R,R--tocopheryl acetate) or synthetic vitamin E acetate derivative 
(all-racemic--tocopheryl acetate) on human cancer development (3). Most recently, a 
randomized, placebo-controlled Selenium and Vitamin E Cancer Prevention Trial 
(SELECT) was conducted to determine whether 200 g of selenium or 400 IU of 
synthetic vitamin E as all-rac--tocopheryl acetate, or combination of both could prevent 
prostate cancer and other diseases in healthy men. This trial which started in 2001 and 
was planned to continue for 12 year was discontinued early in 2008 because there was no 
evidence of benefit from either agent (11). On the other hand, studies using -tocopherol 
(-T) or tocotrienols have demonstrated potent anticancer effects of these compounds in 
various systems. Although not many clinical or observation studies using these molecules 
are available, the CLUE studies epitomize the possible chemopreventive effect of -T in 
human prostate cancer (12, 13). The subjects of these studies were male residents of 
Washington County, Maryland who donated blood in 1974 and 1989. In these subjects, 
higher serum -T level was associated with reduced risk of developing prostate cancer 
(13).  Cell culture studies using various human cancer cells also support anticancer action 
of -T: in human prostate cancer cells, -T induced apoptosis by interrupting de novo 
sphingolipid synthesis pathways (14); in human colon cancer cells, -T induced apoptosis 
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in a caspase-8 dependent manner (15); and in human breast cancer cells, -T induced 
death receptor 5 (DR5)-mediated apoptotic signaling by increasing the expression level 
of DR5 (16).  In previous animal studies in our lab, both liposomal and dietary delivery 
of -T reduced tumor burden in a syngeneic 66cl-4-GFP mouse mammary tumor model 
as well as in the MDA-MB-231-GFP human breast cancer xenograft model (17, 18). 
Notably, anticancer action of -T was antagonized by co-treatment with -T perhaps due 
to the selective metabolism of -T by hepatic cytochrome P450 (CYP) enzymes (18). 
Tocotrienols had not been studied extensively for their possible benefits to human health 
due to their limited amounts in natural sources until tocotrienol-rich fraction (TRF) was 
obtained from palm oil as 68% tocotrienols and 32% -T (19). Although the exact 
anticancer mechanism of TRF or individual forms of tocotrienols need to be better 
understood, a possible therapeutic application of tocotrienols in human cancers has been 
evaluated using various cancer types including breast cancer, colorectal cancer, gastric 
adenocarcinoma, liver cancer, lung carcinoma, pancreatic cancer, and prostate cancer 
(20-26). Possible mechanisms of tocotrienol-mediated inhibition of cell proliferation or 
apoptosis induction have been proposed in neoplastic murine mammary epithelial cells or 
human breast cancer cells. Note should be taken that highly malignant mammary 
epithelial cells are more sensitive to anti-proliferative and apoptotic effects of 
tocotrienols than preneoplastic cells (27). In malignant mammary epithelial cells, -
tocotrienol (-T3) antagonizes phosphatidyl inositol-3 kinase (PI-3K)/Akt and nuclear 
factor-B (NF-B) signaling pathways, and also induces caspase-8 and -3 mediated 
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apoptosis (28, 29). -tocotrienol (-T3) triggers apoptosis which is mediated by 
upregulation of transforming growth factor- receptor II (TGF-RII) and TGF--, 
Fas/CD95-, and c-Jun N-terminal kinase (JNK)-signaling pathways in human breast 
cancer cells (30). -T3 also reduces phosphorylation of retinoblastoma protein (Rb) as 
well as the expression of cyclin D1/cyclin dependent kinase 4 (CDK4), all of which 
induces G0/G1 cell cycle arrest (31). In a human breast cancer xenograft model, oral 
gavage of 1 mg/day/mouse of TRF reduces tumor incidence and the area of tumor surface 
(32) and the dietary delivery of -T3 at 62.5 mg/kg bodyweight significantly inhibits the 
weight of murine melanoma tumors in a syngeneic model (33). In liver or lung 
carcinogenic studies, oral delivery of a tocotrienol mixture in drinking water suppressed 
the incidence of spontaneous liver tumor formation or glycerol-induced lung 
carcinogenesis, suggesting that daily intake of tocotrienols can prevent cancer incidence 
(24). Tocotrienols are also known to inhibit angiogenesis; thus, have been explored for an 
application to suppress tumor malignancy (5, 6). Because of the aforementioned 
advantages to human health, tocotrienols have gained substantial attention during the last 





1.2. Synthetic vitamin E derivatives and their anticancer activities 
1.2.1. Redox-silent vitamin E derivatives and their anticancer activities 
Vitamin E was first discovered in 1922 as a dietary factor required for reproduction in 
rats (2). Due to the essential nature of vitamin E as a micronutrient, total syntheses of 
vitamin E or purification from natural sources were of great economic importance (34). 
To date, the largest amount of manufactured vitamin E is the acetate derivative of 
synthetic vitamin E, namely, all-racemic--tocopheryl acetate (all-rac--T-Ac) which is 
more resistant to oxidative destruction (35). Another synthetic form that is less common 
but also commercially available and resistant to oxidation is R,R,R--tocopheryl 
succinate (-TOS) in which succinic acid is coupled to the C6 on the chroman head via 
an ester bond. After oral intake, these pro-vitamin E forms are liberated into active free 
-T or all-rac--T by pancreatic enzymes in the intestine (36). Intriguingly, the succinate 
derivative but not the acetate form of -T exhibits strong apoptogenic activity in vitro 
and anti-tumor/anti-metastatic effects in vivo (reviewed by (37)). Although -TOS 
exhibits tumor suppressive activity in various preclinical animal studies, its clinical use is 
hindered due to hydrolysis of the critical succinyl moiety by cellular or intestinal 
esterases yielding -T and succinic acid, neither of which has anticancer properties (38). 
To circumvent the hydrolytic inactivation of the active moiety in -TOS, the ester-linked 
succinate moiety at the C6 position of the chroman head was exchanged for an ether-
linked acetate moiety to generate a non-hydrolysable -T derivative, 2,5,7,8-tetramethyl-
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2R-(4R,8R,12-trimethyltridecyl)-chroman- 6-yloxy acetic acid (-tocopheryloxyacetic 
acid or -TEA) (Figure 1.3). Consequently, -TEA is stable as an inducer of apoptosis, 
while -TOS is less effective in several cancers that highly express esterases such as 
ovarian and cervical cancer cells (38). Both -TOS and -TEA display pleiotropic 
anticancer actions selectively to malignant cells: activation of apoptosis, blockage of cell 
survival and cell proliferation, induction of differentiation, blockade of metastasis, and 
sensitization of tumor cells to other chemotherapeutic agents (3).  
 
 
Figure 1.3. Structure of R,R,R--tocopherol derivatives. R,R,R--tocopheryl 
succinate, namley VES  or -TOS, is an ester-linked succinic acid derivative and 




























1.2.2. Anti-tumor effects of -TEA in animal studies 
-TEA has been shown to suppress the growth of tumors in both syngeneic mouse 
mammary tumor models using highly metastatic 66cl-4-GFP and 4T1 cells as well as in 
xenograft models using immune compromised mice transplanted with human breast 
cancer cells (MDA-MB-435-GFP), human prostate cancer cells (PC3-GFP) or cisplatin-
resistant human ovarian cancer cells (A2780-cp70-GFP) (39-43).  -TEA also showed 
preventive effects on skin-tumor development in mice exposed to ultraviolet (UV) for 24-
weeks (44).  Combinational treatment of -TEA with other cancer therapeutics, such as 
9-nitrocamptothecin, celecoxib (a cyclooxygenase-2 inhibitor), cisplatin, and paclitaxel, 
showed better outcomes than single treatments (41, 43, 45, 46). Since -TEA is a   
yellow crystalline chemical which is insoluble in water, delivery of -TEA in animals 
has been tried in several different ways. The first animal study was conducted using 87.5% 
peanut oil with 12.5% ethanol as a solvent for oral gavage of -TEA. Mice bearing 
murine mammary tumors received 5 mg/mouse/day for 13 days but no tumor growth 
inhibition was observed (40). On the other hand, liposomal formulation of -TEA 
delivered by aerosol suppressed tumor growth effectively and also reduced lung 
metastases (40). The estimated amount of aerosolized -TEA delivered per each 
mouse/day was 36 g. Not only aerosol delivery but also the oral gavage of -TEA (5 to 
6 mg/mouse/day) formulated in liposomes exhibited tumor suppressive and metastases 
inhibitory effects in different animal studies (42, 47), suggesting liposomal formulation 
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can be an effective way to deliver lipophilic -TEA. Another approach to -TEA 
administration was by incorporating it into a diet.  Hahn et al. (39) showed that dietary 
delivery of -TEA at a concentration of 3.3 g of -TEA/kg diet (approximately 5 
mg/mouse/day) significantly suppressed the growth of 4T1 mammary tumors in mice. In 
our studies, 250 mg -TEA/kg diet significantly reduced the mammary tumor growth by 
40% compared to the control diet, suggesting that -TEA can be easily translated to the 
clinic as a dietary treatment (39).  
To investigate in vivo antitumor mechanism of -TEA in mouse models, tumor tissue 
sections were analyzed for several different cellular markers including Ki-67 for cell 
proliferation, TUNEL assay for apoptosis, and CD31 for blood vessel formation.  Based 
on several studies, -TEA increased the percentage of tumor cells undergoing apoptosis 
and decreased the number of tumor cells undergoing proliferation. Neither CD31 positive 
cell numbers nor blood volume in tumor showed significant differences from control 
groups (45), indicating that -TEA exerts tumor suppressive effects by directly acting on 
tumor cells rather than targeting blood vessel formation in the tumor.    
1.2.3. Anticancer mechanism of -TEA in cancer cells 
Since -TEA induces tumor cell apoptosis and inhibits tumor cell proliferation in animal 
studies, efforts have been made to identify possible cellular target(s) of -TEA using a 
wide variety of human cancer cell lines. Anderson et al. showed that normal human 
mammary or prostate epithelial cells or non-tumorigenic breast cells did not respond to 
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-TEA action to induce apoptosis, but various types of human cancer cells including 
breast, cervical, ovarian, endometrial, prostate, colon and lung cancer cells underwent 
apoptosis in a dose- and time-dependent manner after -TEA treatment (38).  Since then, 
most of the studies in our lab have focused on indentifying tumor-selective anticancer 
mechanisms of -TEA using various types of human cancer cells including cisplatin-
sensitive and resistant human ovarian cancer cells in cell culture. Cisplatin is a platinum-
based DNA-damaging agent that is used as a first line chemotherapeutic for ovarian 
cancer patients; however, its side effects and intrinsic or acquired resistance limits its use 
in clinical practice (43). Although cisplatin-resistant A2780/CP70 cells are less sensitive 
to -TEA treatment, -TEA works as a proapoptotic agent in both cisplatin sensitive and 
resistant human ovarian cancer cells (48). Therefore, -TEA can be used as a potential 
therapeutic agent that can substitute for or as an adjuvant to the first line 
chemotherapeutic approach. In these ovarian cancer cells, -TEA activates caspase-
dependent proapoptotic pathway by enhancing a cell surface death receptor, Fas signaling 
followed by caspase-8 activation, tBid translocation to the mitochondrial fraction, 
cytochrome C release, caspase-9 activation; as well as caspase-3 activation and PARP 
cleavage (48). -TEA also inhibits prosurvival pathways through the downregulation of 
extracellular signal-regulated kinase (ERK1/2) and protein kinase B (Akt) (48). Further 
studies showed that the expression of epidermal growth factor receptors (EGFR) and anti-
apoptotic proteins such as cellular FLICE-like inhibitory protein (FLIP, a caspase 8 
inhibitor) and survivin were down-regulated following -TEA treatment (49). 
13 
 
Overexpression of EGFR family members and the activation of downstream proteins 
such as Akt, FLIP, and survivin is frequently observed in many types of human cancer 
and directly associated with poor prognosis. Therefore, the ability of -TEA to induce 
apoptosis selectively in cancer cells by activating pro-apoptotic death receptor signaling 
as well as by downregulating pro-survival and anti-apoptotic signaling pathways in 
cancer cells makes -TEA an important candidate as an anticancer drug.  
Since increases in Fas expression at both mRNA and protein levels after -TEA 
treatment was observed in various cancer cell types, the role of Fas signaling in -TEA-
induced apoptosis was studied using human breast and prostate cancer cells. Fas-
neutralizing antibodies or silencing Fas or Fas ligand (FasL) using small interfering RNA 
(siRNA) partially protect cells from the apoptosis induced by -TEA treatment (48, 50). 
Several studies reported that c-Jun N-terminal kinase (JNK), a stress-activated protein 
kinase, plays a critical role in -TEA-induced apoptosis in various cancer cell types (30, 
48, 50); however the exact target of JNK activated by -TEA was not very clear until Jia 
et al. found the link between JNK activation and Fas signaling (50). In human prostate 
cancer cells, Fas not only activates caspase 8 through the classical death receptor 
signaling pathway followed by caspase 9 and 3 activations, but also associates with Daxx, 
a death domain associated protein which leads to the activation of JNK after -TEA 
treatment. Interestingly, c-Jun activated by JNK upon -TEA treatment directly binds to 
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the promoter region of Fas and Fas L suggesting the possibility of a positive feedback 
loop that further amplifies the apoptotic response triggered by -TEA in cancer cells (50).  
cDNA microarray analyses of human breast cancer cell-line, MDA-MB-435 treated with 
-TEA added more insights into understanding the pleiotropic anticancer activities of -
TEA in cancer cells (51).  Over 400 genes were modulated after -TEA treatment and 34 
genes have been further classified for their functions regarding involvement in apoptosis, 
cell-cycle regulation, signal transduction, transcriptional regulation, cell adhesion and 
motility, and membrane trafficking (51). Among these genes, the gene coding for NOXA, 
a pro-apoptotic and BH3-only member of the Bcl-2 family has been shown to be 
upregulated in a JNK-dependent manner after -TEA treatment of human breast cancer 
cells (51). In these cells, JNK also regulated the expression of p73, a member of the p53 
family which can recognize p53 response elements. It is still unclear whether p73 directly 
binds to the promoter region of NOXA; however data suggest that the activation of JNK 
is required for the upregulation of p73 which affects increased NOXA level as well as the 
apoptotic response after -TEA treatment (51). Based on these cellular studies, proposed 




Figure 1.4. Schematic diagram of anticancer action of -TEA via inhibiting pro-
survival pathways as well as enhancing death receptor signaling pathways in human 
cancer cells. -TEA decreases the protein level of EGFR family members; downregulates 
the phosphorylation of ERK1/2 and Akt; and also reduces expression of inhibitors of 
apoptosis, such as c-FLIP and survivin. At the same time, -TEA activates Fas/FasL 
mediated apoptosis signal transduction followed by caspase 8 activation which eventually 
causes mitochondria-mediated caspase 9 activation. Fas signaling enhanced by -TEA 
induces activation of JNK and c-Jun which directly increase gene expression of Fas and 





























1.3 Endoplasmic reticulum stress and effects on cell fate 
1.3.1. Unfolded protein response 
The endoplasmic reticulum (ER) serves critical functions in synthesis and folding of 
secreted, membrane-bound, or organ targeted proteins and their transport; metabolic 
processing of lipids, steroids and carbohydrates; as well as, regulation of intracellular 
calcium concentration in eukaryotic cells (52, 53). Disruption of ER functions under 
various cellular stresses such as hypoxia, glucose deprivation, depletion of calcium ions, 
or viral infection can increase unfolded or misfolded protein build-up within the ER 
causing further ER stress followed by activation of the unfolded protein response (UPR). 
The lumen of the ER contains a chaperon, called glucose-regulated protein of 78 kDa 
(GRP78) also known as BiP, that is a critical regulator of intracellular signaling pathways 
under ER stress. In unstressed cells, GRP78 physically interacts with three ER resident 
transmembrane transducers: pancreatic ER kinase-like ER kinase (PERK), inositol-
requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) (54). When 
unfolded proteins accumulated in the ER, GRP78 is redirected to aid protein folding 
thereby releasing these transducers, which allows their activation. Through the UPR, cells 
can adapt to environmental changes by enhancing protein folding capacity; activate NF-
B signaling pathway that induces genes required for host defense and survival; and 




1.3.2. Mediators of UPR 
Under ER stress, global gene expression is halted at the translational level by PERK, a 
Ser/Thr kinase that accumulates and is activated after its detachment from GRP78. The 
major substrate of PERK is eukaryotic translation initiation factor 2 (eIF-2) which 
becomes phosphorylated by PERK and is thereby rendered unable to deliver initiator 
met-tRNA to the translational machinery (55). Certain proteins such as activating 
transcription factor 4 (ATF4) gain advantage by the inactivation of eIF-2. ATF4 is a basic 
leucine zipper (bZIP) transcription factor which targets genes involved in the restoration 
of cellular redox homeostasis and protein folding including ER chaperons, GRP78 and 
GRP94 (53).   
IRE1, the other transducer oligomerized upon release from GRP78, contains both a 
Ser/Thr kinase domain and an endoribonuclease domain (52). The Ser/Kinase domain of 
IRE1 autophosphorylates itself, which not only activates its endoribonuclease activity but 
also recruits adaptor protein, tumor necrosis factor receptor associated receptor-
associated factor-2 (TRAF2) followed by apoptosis-signal-regulating kinase 1 (ASK1) 
recruitment (56). ASK1, an upstream kinase of JNK and p38 MAPK, is activated by 
various stress signals including oxidative stress and calcium overload (57). The major 
consequence of ASK1 activation under ER stress is activation of cell death signaling 
pathways mainly via JNK which modulates activity of BCL2 protein family members 
(58). Although a role for p38 MAPK in ER-stress mediated apoptosis is yet to be 
confirmed, overexpression and knockout studies showed that ASK1 plays a pivotal role 
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in ER-stress mediated apoptosis (58). While IRE1 transduces cell death signaling via 
TRAF2-ASK1-JNK, the endonuclease activity of IRE1 processes the mRNA encoding 
X-box-binding protein (XBP1) to generate a splice variant encoding an active 
transcription factor which regulates expression of several genes involved in ER-
associated degradation (ERAD) and proper protein folding (58, 59).   
GRP78 also releases ATF6, a b-ZIP family member transcription factor, similar to ATF4. 
When detached from ER membrane, ATF6 translocates to the Golgi apparatus for 
proteolytic processing of a juxtamembrane site resulting in an active transcription factor. 
The active form of ATF6 is released into the cytosol and translocates to the nucleus (53). 
Target genes of ATF6 include XBP1, GRP78 and protein disulfide isomerate (PDI), all of 
which regulate ER homeostasis by increasing ER chaperon activity and degradation of 
misfolded proteins (53).  
1.3.3. C/EBP homologous protein (CHOP), a component of ER stress-mediated 
apoptosis 
CHOP, also known as growth arrest- and DNA damage-inducible gene 153 (GADD153), 
is a 29 kDa transcription factor upregulated at multiple levels during ER stress (60). The 
promoter region of CHOP has at least four distinct cis-acting elements to which ATF4, 
ATF6 and XBP-1 bind (61).  In addition, p38 MAPK, one of the downstream kinases 
activated by IRE1 under ER stress phosphorylates Ser78 and Ser 81 of CHOP thereby 
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enhancing CHOP transcriptional activity (61). Thus, CHOP is a key transcription factor 
that is highly induced and activated during ER stress.  
The role of CHOP upregulation during ER stress has been studied in various systems. A 
dominant negative form or targeted disruption of CHOP delays ER stress-induced cell 
death, whereas overexpression of CHOP markedly reduces cell viability (62, 63), 
suggesting that CHOP connects persistent and overwhelming ER stress to the onset of 
cellular apoptosis. Target genes of CHOP related to UPR include the mammalian 
homolog of yeast ER oxidase (ERO1) that is responsible for the accumulation of 
reactive oxygen species in ER-stressed cells; and GADD34, a regulatory protein that is 
required to reverse the early translational repression during various cellular stresses 
including UPR (60). CHOP also regulates gene expression of BCL2 protein family 
members: Bcl-2, an anti-apoptotic protein, is down-regulated by CHOP although it is not 
clear if CHOP directly binds to the promoter sites of Bcl-2; and Bim, a proapoptotic BH3 





Figure 1.5. Schematic diagram of transcriptional induction of CHOP/GADD153 under 
ER stress. When unfolded or misfolded proteins accumulated in the ER, GRP78, an ER 
chaperon relocates to promote protein folding and dissociates from three transducers, PERK, 
ATF6, and IRE1 followed by activation of the UPR response. When released from GRP78, 
PERK phosphorylates eIF-2 which induces global translational suppression and the 
induction of ATF4. IRE1 has both a kinase activity as well as an endoribonuclease activity. 
While ASK1 phosphorylated and activated by IRE1 further activates downstream kinases, 
Xbp-1 mRNA is processed by endoribonuclease acvitiy of IRE1 and is translated into a 
stable transcription factor. ATF6 is translocated from ER to Golgi for proteolytic processing 
and then localized into the nucleus for transcriptional regulation. All transcription factors, 
ATF4, ATF6 and XBP-1, directly bind to the cis-acting elements of CHOP and induce its 
expression (adapted from (61)).   
 
1.4. Role of TNF-related apoptosis inducing ligand (TRAIL) in apoptosis  
Accumulation of unfolded proteins in ER
Grp78 binds to unfolded proteins &
dissociates PERK, ATF6, Ire1
Transport of ATF6
to Golgi




























1.4.1. Pathways of apoptosis  
Apoptosis, a well characterized process of programmed cell death, occurs during 
embryogenesis and metamorphosis, and helps to maintain tissue homeostasis (66, 67). 
Unlike necrosis which is generally mediated by external factors such as injuries or 
infection and subsequent inflammation, apoptosis is a highly ordered process regulated 
by complex and sophisticated pathways which eventually lead to characteristic 
morphological changes of a cell: dense cytoplasmic organelles, DNA fragmentation, 
chromatin condensation, cellular blebbing and shrinkage (67, 68).  
Biochemically, apoptotic pathways involve hierarchical activation of cysteine-dependent 
aspartate-directed proteases (caspases), and this sequential proteolytic cascade amplifies 
the apoptotic signal leading to rapid cell death (67, 69). Caspases are synthesized as 
inactive zymogens with prodomains which are bound to regulatory proteins preventing 
unregulated activation (68). Upon apoptotic triggers, initiator caspases such as caspase-8 
or -9 are recruited to upstream adaptor molecules which provide a platform for initiation 
of autocatalytic cleavage of their prodomains followed by proteolytic activation of 
effector caspases such as caspase-3 or -7 resulting in the execution steps of apoptosis (70).  
Depending on the origin of apoptotic cue, initiator caspases can be activated by two main 
pathways: the intrinsic pathway activated by DNA damage and the extrinsic pathway 
involving interaction between transmembrane death receptors and extracellular ligands 
(67). The intrinsic pathway is a mitochondrial-initiated multi-step process activated by 
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various cellular stresses including UV radiation, chemotherapy, starvation, and hypoxia 
(68). Members of the Bcl-2 protein family control and regulate mitochondrial membrane 
permeability (67). Loss of mitochondrial membrane potential and permeability promotes 
release of factors into the cytoplasm forming a protein complex; namely, the apoptosome 
that activates initiator caspase-9 and effector caspases (68). The extrinsic pathway 
involves engagement of cell surface death receptors (DR) with the tumor necrosis factor 
(TNF) family of cytokines including TNF, Fas ligand (FasL), and TNF-related apoptosis-
inducing ligand (TRAIL) (71). This ligand-receptor interaction induces formation of the 
death inducing signaling complex (DISC) comprised of multimerized death receptors and 
death domain (DD)-containing adaptor proteins such as Fas-associated death domain, 
FADD (72). DISC recruits procaspase-8, and activates caspase-8 and other effector 
caspases subsequently. Crosstalk between extrinsic and intrinsic pathways is mediated by 
the proapoptotic Bcl-2 homology 3 (BH3)-only protein, Bid, when it is cleaved by 
extrinsic pathway activated-caspase 8 (72). Truncated Bid (tBid) translocates to 
mitochondrial membrane and promotes intrinsic apoptotic signaling pathway by 
employing proapoptotic Bcl-2 family proteins, Bax and Bak resulting in mitochondrial 




1.4.2. TRAIL and death receptors 
TRAIL, also known as Apo2L, is a transmembrane protein and a member of the TNF 
superfamily which shares conserved C-terminal domains required for receptor binding 
(68). A soluble form of TRAIL has been found in serum following proteolytic cleavage 
of its extracellular domain by activated monocytes and neutrophils (73). So far, two 
agonistic receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5) and three antagonistic 
receptors (TRAIL-R3/DcR1, TRAIL-R3/DcR2 and osteoprotegerin/OPG) have been 
reported to interact with human TRAIL (74). Both DR4 and DR5 are type I 
transmembrane proteins containing an extracellular cysteine-rich domain and a 
cytoplasmic death domain (DD). The crystal structure of TRAIL and DR5 revealed that 
the trimeric ligand is interdigitated with three monomeric receptors (73). Trimerized 
receptor death domains recruit FADD through its own DD at the C-terminus followed by 
the recruitment of procaspase-8 via N-terminus death effector domain (DED). On the 
other hand, antagonistic receptors, DcR1 or DcR2 lack functional death domains; and 
thus, impair the downstream apoptotic signaling cascade (74). 
1.4.3. TRAIL in cancer therapy 
TRAIL mRNA and protein are present in a diverse range of tissues; however, cell surface 
expression of TRAIL is not observed in resting normal cells which express high level of 
decoy receptors, DcR1 or DcR2, sequestering TRAIL (68). Some subsets of macrophages, 
lymphocytes and dendritic cells when activated by proinflammatory cytokines or virally 
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infected fibroblasts upregulate their cell surface expression of TRAIL and/or death 
receptors, implicating a possible role of TRAIL in innate immunity (68). Importantly, 
studies have shown that some types of cancer cells express high levels of DR4 or DR5 
and low levels of decoy receptors (68). Therefore, TRAIL has been recognized as a 
potential anti-tumor therapeutic with the major advantage that it will trigger apoptosis 
selectively in cancer cells producing little to no toxicity in normal cells (74). The first 
attempt to use recombinant soluble TRAIL as an anticancer agent in clinical studies 
failed to show promising effects due to its short half-life and rapid clearance from 
circulation (75). Nevertheless, different formulations of TRAIL as well as alternative 
approach to targeting TRAIL signaling are currently in phase I/II clinical studies (75). 
Trials using recombinant human TRAIL (rhTRAIL), a receptor-selective variant of 
TRAIL, as well as DR4- and DR5-selective agonistic antibodies as single agents or in 
combination therapy are being tested for ability to improve patient disease free survival 
(75).    
1.4.4. Cancer cell resistance of TRAIL 
One of obstacles of targeting TRAIL signaling as an anticancer approach is that 
numerous tumors are not responsive to TRAIL-induced apoptosis due to several different 
inhibitory mechanisms (73). One of the proposed inhibitory mechanisms is that decoy 
receptors (DcR) in cancer cells may compete with agonistic death receptors for TRAIL 
binding; therefore, the ratio of DRs/DcRs at the cell membrane may determine sensitivity 
to TRAIL in some cancers that express both DRs and DcRs (74). Defective DRs may also 
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contribute to TRAIL-resistance. Best known examples are breast cancer cells that 
generally express very low level of DcRs but display resistance to TRAIL due to 
defective DR4 expression and/or loss of cell surface DRs (76). In addition to low or 
deficient DR4 expression, polymorphic DR4 death domains contribute to TRAIL 
insensitivity in several different types of cancer cells (77). Another important determinant 
is the presence of or defective internal regulators. Cells with inactive caspase-8 due to 
epigenetic silencing fail to transmit TRAIL-induced apoptotic signaling (78); and 
elevated expression of c-FLIP (FLICE-inhibitory protein), an inhibitor of caspase-8 
activation, also shows correlation with TRAIL-resistance (77). High expression of 
inhibitor-of-apoptosis proteins (IAP), such as X-linked IAP (XIAP) or anti-apoptotic Bcl-
2 proteins are also linked to TRAIL resistance (75). Therefore, various strategies are 
currently being tested using chemotherapeutics as well as natural compounds to restore 





Figure 1.6. Mechanisms of TRAIL resistances (in orange color) and therapeutic strategies to 
restore TRAIL sensitivity (in blue color).  Binding of TRAIL to DR4/DR5 triggers apoptosis in 
tumor cells by recruiting FADD to form the death inducing signaling complex (DISC) which attracts 
procaspase-8 and initiates its activation. Active caspase-8 can directly activate execution caspases 
and/or cleave Bid to tBid which translocates to mitochondrial membranes leading to the formation of 
Bax/Bak pores in the outer mitochondrial membrane. Mitochondrial membrane permeability is 
increased and cytochrome c is released into the cytosol triggering formation of apoptosomes and 
activation of caspase-9 followed by activation of executioner caspases (caspase-3 or -7). Decoy 
receptors (DcRs) can block the activation of DR4/DR5 when expressed at high levels in some tumor 
cells. Novel therapies using DR4/DR5 selective TRAIL variant or receptor specific agonistic 
antibodies are currently under investigation. Several DNA damaging reagents are also known to 
induce increases of DR4/DR5 levels on the cell surface membrane thereby potentiating TRAIL 
induced apoptosis. Downstream signaling of DR4/DR5 can be blocked by c-FLIP which can be 
targeted by several chemotherapeutic agents shown to down-regulate c-FLIP. Anti-apoptotic Bcl-2 
family proteins (Bcl-xL, Mcl-1 and Bcl-2) can block the delivery of apoptotic signals, which can be 
overcome by small molecule Bcl-2 inhibitors. Inhibitor of apoptosis proteins (IAP) are another class 
of downstream inhibitors of TRAIL-induced apoptosis. Several natural compounds and therapeutic 
agents are proposed to re-sensitize cells displaying IAPs-mediated TRAIL resistance. In p53 
expressing tumor cells, DNA damaging agents and radiation therapy can sensitize cells to TRAIL-
induced apoptosis by up-regulating several genes including DR4/DR5, and the BH3-only proteins Bax, 
















































1.5. Objective and specific aims 
Studies in our lab have been focused on the therapeutic potential of a non-hydrolyzable 
ether derivative of -T (-TEA: 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)-
chroman-6-yloxy acetic acid or -tocopheryloxyacetic acid) which has an acetic acid 
moiety attached via an ether-linkage at the C6 position of the -TEA chroman head (3, 
37). -TEA displays pleiotropic anticancer actions selectively to malignant cells: 
induction of apoptosis, blockage of cell survival, inhibition of cell proliferation, induction 
of differentiation, blockade of metastasis, and sensitization of tumor cells to other 
anticancer drugs (3). Considering that -TEA exhibits a broad spectrum of anticancer 
activity while the parent compound -T has modest to no anticancer activity and lacks 
any consistent documentation of anticancer activity in humans, modification of 
tocotrienols known to have beneficial effects on inhibiting cancer cell growth posses an 
intriguing possibility for the development of more effective vitamin E-derived therapeutic 
drugs. In addition, characterization of the anticancer mechanism of different forms of 
natural vitamin E as well as the interactions between/among various forms of natural 
vitamin E during metabolism need to be investigated to identify the most beneficial 
vitamin E form for anticancer approach, as well as to increase public understanding of the 
advantages and disadvantages of vitamin E supplementation. 
Thus, my studies focused on the following: 1) define the potential of tocotrienol 
derivatives to serve as potent anticancer drugs; 2) identify the anticancer mechanisms of 
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the parent tocotrienol compounds to better understand their mode of action; and 3) 
evaluate the anticancer effects of -T, the most abundant form of vitamin E in US diet, 
and define its mechanism(s) of action. Through these studies, we have gained important 
insights into the development of novel vitamin E derivatives as cancer therapeutics, and 
also obtained a better understanding of the anticancer mechanisms of action of different 
forms of natural vitamin E.  
Contents in Chapter 1 have focused on background information and review of the 
literature. Chapter 2 is focused on the development of novel tocotrienol derivatives and 
their effects on human breast cancer cells and mouse mammary tumor cells in cell culture. 
Antitumor effects of each derivative in a syngeneic mouse mammary tumor model are 
also addressed. Chapter 3 describes anticancer mechanisms of tocotrienols in breast 
cancer cells in cell culture and the role that endoplasmic reticulum (ER)-stress plays in 
tocotrienol-mediated apoptosis. Chapter 4 documents the anticancer effect of -T in 
human breast cancer cells and in a mouse xenograft tumor model. Chapter 5 summarizes 




Chapter 2. Anti-cancer and antiangiogenic effects of novel tocotrienol derivatives  
Breast cancer is the most common cancer diagnosed in US women. Even though early 
diagnosis has reduced the rate of metastasis and mortality, breast cancer still ranks as the 
second leading cause of death from cancer in US women. There is a need for better 
chemotherapeutic agents for this disease. Previous studies in our lab have characterized 
the anticancer efficacy of a novel non-hydrolysable ether derivative of R,R,R,-alpha-
tocopherol, namely -TEA (2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl) 
chroman-6-yloxy acetic acid). In this study, non-hydrolysable ether derivatives of other 
forms of vitamin E; namely, -tocotrienol (-T3) and -tocotrienol (-T3) were 
synthesized and tested for their anticancer activities in comparison to -TEA. These 
novel tocotrienol agents exhibited strong anti-proliferative and proapoptotic activities in 
murine mammary cancer cells and in both estrogen receptor (ER) positive and negative 
human breast cancer cells. Notably, studies in human vascular endothelial cells 
(HUVECs) showed that tocotrienol derivatives exhibited strong antiangiogenic activities 
which were markedly improved over those of the parent compounds. An antitumor 
efficacy study using the 66cl-4-GFP syngeneic mouse mammary tumor model showed 
that each tocotrienol derivative, when delivered in the diet, significantly suppressed 
mammary tumor growth as much as -TEA; however serum and tissue concentration of 
these novel derivatives were lower than those of -TEA, which suggest that the next 




Vitamin E refers to a group of natural compounds which share similar structure, a 
chromanol ring and an aliphatic side chain. Vitamin E is divided into two subgroups 
which consist of tocopherols and tocotrienols, and each subgroup includes four individual 
forms as -, -, γ- and -tocopherols and -, -, γ- and -tocotrienols respectively. 
Efforts to prove a possible role for vitamin E in cancer prevention have been made; 
however neither preclinical nor clinical studies support a beneficial effect of the major 
form of vitamin E (-T), synthetic vitamin E (all-rac--tocopherol) or their acetate 
derivatives on human cancer development (3). On the other hand, the other subgroup of 
vitamin E, tocotrienols, although not as abundant as -T, exhibits various distinctive 
functions not shared by -T, such as neuroprotective, anticancer, and cholesterol-
lowering activities (4). While -tocotrienol (-T3) has potential to prevent 
neurodegeneration, - and -tocotrienols (-T3, -T3) are reported to display potent 
anticancer properties (4, 20). Studies using human breast cancer cells or murine 
neoplastic mammary epithelial cells demonstrated that both -T3 and -T3 exert anti-
proliferative and pro-apoptotic effects (28-30). The intracellular mechanisms of -T3-
mediated growth inhibition is via antagonizing phosphatidyl inositol-3 kinase (PI-
3K)/Akt and NF-B signaling pathways. These pathways play a critical role in growth 
factor-induced cell growth and survival, and are frequently mutated or amplified in 
human cancers (29). Another unique property of tocotrienols is the inhibition of 
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angiogenesis which is believed to be the major therapeutic target against various human 
disorders including cancer, diabetic retinopathy, and rheumatoid arthritis (6).  
Studies in our lab have been focused on the therapeutic potential of redox-silent vitamin 
E derivatives as anticancer agents (3, 37). To date, -tocopheryl succinate (VES or -
TOS) and a non-hydrolyzable ether derivative of -T (-TEA: 2,5,7,8-tetramethyl-2R-
(4R,8R,12-trimethyl-tridecyl)chroman-6-yloxy acetic acid or -tocopheryloxyacetic 
acid) are the most studied compounds. Although VES exhibits tumor suppressive activity 
in various preclinical animal studies, its clinical use is hindered by the hydrolysis of the 
critical succinyl moiety by cellular or intestinal esterases yielding -T and succinic acid, 
neither of which have anticancer properties (38). In contrast, the C6 position of the -
TEA chroman head is attached to an acetic acid moiety via an ether-linkage which is 
stable in hydrolytic environments. Consequently, -TEA is stable as an inducer of 
apoptosis while VES is less effective in several cancers that highly express esterases such 
as ovarian and cervical cancer cells
 
(38, 43). Considering that both VES and -TEA 
exhibit a broad spectrum of anticancer activities while the parent compound -T has 
modest to no anticancer activity and lacks any consistent documentation of anticancer 
activity in humans, modification of the other natural vitamin E compounds known to 
have beneficial effects on cancer intervention posses an intriguing possibility for the 
development of more effective vitamin E-based therapeutic drugs.  
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In this study, we chemically modified -T3 and -T3 to generate redox-silent tocotrienol 
derivatives. These novel compounds were tested for their anticancer and anti-angiogenic 
activities in murine mammary cancer cells, human breast cancer cells, and human 
umbilical vascular endothelial cells in cell culture. Finally, tumor-suppressive activities 
of novel tocotrienol derivatives compared to the parent compound or -TEA were tested 
in the 66cl-4-GFP syngeneic murine mammary tumor model.  
 
 
Figure 2.1. Structures of novel tocotrienol derivatives. The hydroxyl group at the 
C6 position of the chroman head of -T3 and -T3 was modified to become an 
ether-linked acetic acid, generating R--tocotrienyl-oxyacetic acid (-T3EA) and R-
-tocotrienyloxyacetic acid (-T3EA), respectively. The purity of each compound 




























2.2. Materials and Methods 
2.2.1. Chemicals 
-T3 and -T3 used to synthesize novel derivatives were kindly provided by the 
Malaysian Palm Oil Board (Malaysia). The ether-linked acetic acid derivative of -T3, 
namely -T3EA, was synthesized by Dr. Jeffrey Atkinson (Department of Chemistry, 
Brock University, St. Catharines, Ontario, Canada) and the derivative of -T3, namely -
T3EA, was prepared by Dr. Hakjoong Kim (Department of Chemistry and Biochemistry,  
University of Texas at Austin, Austin, TX) based on the chemical synthesis of -TEA as 
described previously (40). The purity of new derivatives was determined using NMR 
spectroscopy. The structure and the purity of each ether-linked acetic acid derivative are 
shown in Figure 2.1. Relatively low purity (>80%) of -T3EA is due to impurities in the 
parent compound, -T3. The major impurity (approximately 10%) in -T3 is considered 
to be -T3 based on NMR analyses. 
2.2.2. Cell culture and reagents 
The source and culture conditions for 66cl-4-GFP murine mammary tumor cells were 
previously described (79). MDA-MB-231 and MCF-7 human breast cancer cells were 
obtained from the American Type Culture Collection (ATCC), cultured and maintained 
in MEM medium as previously described (18). All media were supplemented with 10% 
fetal bovine serum (HyClone Laboratories, Logan, UT), 100 U/ml penicillin, and 100 
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mg/ml streptomycin.  Human mammary epithelial cells (HMEC; Cooperative Human 
Tissue Network, Birmingham, AL) were primary cultures of human mammary cells 
derived from normal mammoplasty specimens as described previously (80). For 
treatments, FBS was reduced to 2% to better mimic the in vivo low serum exposure of 
these cell types. Human umbilical vascular endothelial cells (HUVECs) were purchased 
from Lonza (Basel, Switzerland), cultured and maintained in EGM2 endothelial cell 
medium (Lonza) following manufacturer‟s instructions. 
2.2.3. Cell proliferation assay (MTS assay) 
Effect of novel derivatives on cell proliferation was assessed in cell culture. MDA-MB-
231 or MCF-7 cells at 5X10
3
/well, 66cl-4 cells at 10
4
/well and HUVECs at 2.5X10
5
/well 
were seeded in 96-well plates. Cells were treated with a range of concentrations from 5 to 
40 µM of each compound. Control cells were treated with the vehicle (ethanol) at a final 
concentration of 0.1%. After 24 hrs, viable cells were measured using CellTiter 96®  
AQueous Non-Radioactive Cell Proliferation Assay (Promega, Corp., Madison, WI) 
following manufacturer‟s instructions. The percentage of viable cells at each 
concentration was calculated by dividing color absorbance (A490) of treated cells by that 
of control cells. The IC50 of each compound was determined using BioDataFit 1.02 




2.2.4. Evaluation of apoptosis [Annexin V-FITC/Propidium iodide (PI) assay] 
Percentage of apoptotic cells after treatments was determined using an Annexin V-
FITC/PI assay as previously described (16). Briefly, cells were collected at indicated time 
points and resuspended in Annexin V binding buffer (10 mM HEPES (pH7.4), 150 mM 
NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2). Cells were incubated with Annexin V-
FITC (Invitrogen, CA) for 8 minutes at room temperature. Cells were then diluted in PI 
solution (50 ng/mL in PBS) and fluorescence was measured with flow cytometer 
(FACSCalibur, BD Biosciences, San Jose, CA). Data were analyzed using CellQuest 
software (FACSCalibur, BD Biosciences). 
2.2.5. In vitro wound healing assay  
HUVEC migration was assessed using a wound healing assay as described by Staton et al. 
(81). Cells were seeded onto 24-well plates and permitted to reach confluence. Using a 
sterilized 500 l pipet tip, a straight line clearance of cells was made through the cell 
monolayer. The wounded cell monolayer was treated with 2.5, 5 or 10 M of each 
compound and incubated for 15 hrs. Wounded morphologies at time 0- and 15-hr of 
treatment were recorded with a digital camera (Olympus DP71) connected to an inverted 
microscope (Olympus 1X71). Treatments were performed in triplicate. The cell-free area 
was analyzed using ImageJ 1.38x software (NIH, USA). The degree of cell migration was 




2.2.6. In vitro tube formation assay 
HUVEC tube formation was assessed as described by Yamagishi et al. (82). Wells of 96-
well plates were coated with matrigel (30 l/well) which was allowed to solidify for at 
least 1 hr at 37C. HUVECs were prepared by trypsinization and seeded onto the 
matrigel-coated well with 5 M of each vitamin E derivative. Control cells were treated 
with 0.1% ethanol. Treatments were performed in duplicate. After 18 hrs, each well was 
photographed and the tube formation was evaluated by counting the number of tube 
nodes manually. 
2.2.7. Animal study 
The animal study was conducted in accordance with “Guidelines for the humane 
treatment of animals” as designated by the University of Texas Institutional Animal Care 
and Use Committee. Female BALB/c mice at 6 weeks of age were purchased from 
Jackson Laboratories (Bar Harbor, ME). To exclude any possible interference from 
vitamin E supplementation, upon arrival, the animals were fed adjusted vitamin E diet 
(Harlan Teklad TD.08228, Madison, WI) which consisted of a tocopherol-stripped semi-
purified AIN-76A diet with 30 IU/kg diet of all-racemic--tocopheryl acetate to meet the 
nutrient requirement of laboratory mice (83). 66cl-4-GFP cells were harvested and 
resuspended at a density of 2X10
5
 cells/100 µl cell medium without any serum or 
antibiotics. Mice were injected subcutaneously with 2X10
5
 cells in the inguinal area at a 
point equal distant between the fourth and fifth nipples on the right side. Tumor size was 
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measured using calipers and calculated according to the equation V= (X
2
Y)/2, where V is 
the volume of each tumor, X is the smaller diameter, and Y is the larger one (79). When 
tumors reached an average volume of 1 mm
3
, mice were randomly assigned to treatment 
groups (10 animals/group): Basal diet (vitamin E adjusted diet), -TEA, -T3, -T3, -
T3EA or -T3EA containing diets. Each group received their respective diets for 21 days. 
For -TEA, -T3, -T3, -T3EA or -T3EA containing diets, each compound was 
incorporated into the adjusted vitamin E diet by Harlan Teklad at a concentration of 250 
mg of each compound/kg diet. The average amount of food consumption during the study 
was 2.60.3 g/day/mouse, which provided approximately 0.65 mg of each compounds 
per mouse on a daily basis. This amount is the equivalent to a daily intake of 134 mg of 
each compound in humans based on body surface area equivalency (84). For reference, a 
typical soft gel capsule of vitamin E contains 268 mg of R,R,R--tocopherol (400 IU). 
Tumors were measured every other day and body weights were measured on a weekly 
basis. Animals were euthanized after 22 days of treatment. 
2.2.8. Immunohistochemistry to detect endothelial cell maker (CD31) 
Primary tumors from 5 individual mice in each group were collected at the time of animal 
sacrifice and fixed in 10% formalin. Samples were processed for immunohistochemical 
analyses by the Histological & Tissue Processing Facility Core 3 at the University of 
Texas M.D. Anderson Cancer Center-Science Park Research Division (Smithville, TX) 
as previously described (45). Briefly, deparaffinized tumor sections (5 m) were 
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examined for blood vessel density using antibody to endothelial antigen CD31 as an 
indicator of small capillaries. Three fields (X100) per tumor were examined for CD31 
stained microvessels. Quantification of vessels was performed using the ImageJ 
(http://rsbweb.nih.gov/ij) „Analyze Particles‟ function without any manipulation in 
brightness or contrast as described by Vlahovic et al. (85). 
2.2.8. Measurement of tissue concentration of tocotrienols or vitamin E derivatives 
Primary tumors, liver, lung, heart and kidney from 5 individual mice in each group were 
collected at the time of animal sacrifice. Collected tissues were snap frozen in liquid 
nitrogen and stored at -80C until analyzed. Lipids from each tissue were extracted as 
described previously (38). The concentration of each compound per gram tissue was 
measured by an internal standard method using reverse-phase HPLC with fluorometric 
detection. The mobile phase consisted of 96% methanol (HPLC grade; EMD Bioscience, 
NJ), 4% water, and 0.001% glacial acetic acid. Samples were separated on a Waters 
Spherisorb ODS-2 column (Alltech, IL). All compounds were detected at the excitation 
and emission wavelengths of 260 and 320 nm respectively. The amount of individual 
compounds per gram tissue was calculated based on the internal standard method using 
-T as the internal standard (38).   
2.2.9. Determination of lung metastases 
The number of metastatic foci in the left lung lobe was evaluated using fluorescence 
microscopy (X100) as previously described (41, 79). Metastatic foci on both sides of the 
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flattened tissue (10 tissues/group) were scored. Based on the typical 66cl-4-GFP cell size 
of 10 to 20 µm, only 10 m or larger foci were counted.   
2.2.10. Statistical analysis 
Tumor growth was analyzed using one-way analysis of variance (ANOVA) with 
TUKEY‟s post-hoc test using SPSS software (SPSS Inc, Chicago, IL). Differences in 
number of TUNEL and Ki-67 positive cells were determined by t-test (two-tailed, non-
paired) using Prism software version 4.0 (Graphpad, San Diego, CA). A level of P<0.05 
was regarded as statistically significant. Student t-test (two-tailed, unpaired) was used to 






2.3.1. Novel tocotrienol derivatives inhibited cell proliferation in murine mammary 
cancer cells and human breast cancer cells.  
For comparison of anti-proliferative effects of new derivatives, murine mammary cancer 
cells (66cl-4) and human breast cancer cells (MCF-7 and MDA-MB-231) were treated 
with various concentrations of novel vitamin E derivatives, and assessed for cell growth 
inhibition using CellTiter 96®  AQueous Non-Radioactive Cell Proliferation Assay 
(Promega, Corp., Madison, WI). Cell proliferation was inhibited in a dose-dependent 
manner after 2 days of treatment. Notably, IC50 values of new compounds for growth 
inhibition were significantly lower than that of -TEA in all cell lines tested (Figure 
2.2.A). In comparison to the parent compounds, -T3EA had significantly lower IC50 
value compared to -T3 (p<0.01, t-test), while -T3EA and -T3 had similar growth 
inhibitory effects in human breast cancer cells (Figure 2.2.B). In human immortalized 
mammary epithelial cells (MCF-10A) and normal mammary epithelial cells (HMEC), the 
IC50 of each compound was higher than that in cancer cell lines (Table 2.1), which 
suggest that malignant cells are more sensitive to the growth inhibitory effects of natural 





Figure 2.2. Comparison of IC50 for each novel compound to -TEA (A) or to 
the parent tocotrienol (B). Cells were seeded in 96-well plates and treated with 
a range of concentrations from 0.6125 to 80 µM of -TEA, -T3EA, -T3EA, -
T3 or -T3 for 2 days. Control cells were treated with the vehicle (ethanol) at a 
final concentration of 0.1%. Viable cells were determined using CellTiter 96®  
AQueous Non-Radioactive Cell Proliferation Assay. Data are depicted as mean  
SD for three independent experiments. The asterisk (*) indicates significant 
difference from -TEA treatment (A) or the parent compound of each derivative 

















































Table 1. Comparison of IC50 (M) of natural vitamin E compounds and their 
derivatives using several different human cell lines and primary culture of human 
mammary epithelial cells (mean  SD, n=2 or 3). 
Compound 
Cell lines 




 N.I. N.I. N.I. 
-TEA > 80 
b
 39.8  0.5 20.0  0.1 19.4  0.3 
-T3 > 80 > 80 20.0  0.2 19.7  0.5 
-T3EA 19.8  0.2 19.6  0.3 6.6  2.3 6.3  2.0 
-T3 19.7  0.2 20.9  0.3  10.1  0.0 8.8  2.1 
-T3EA 20.4  0.6 20.4  0.3 8.1  3.0 8.1  2.8 
a
 N.I.: No inhibition of cellular proliferation was observed at the highest concentration tested (100 
µM) . 
b











2.3.2. Novel tocotrienol derivatives induced apoptosis in human breast cancer cells.   
Previous studies in our lab showed that -TEA is a potent inducer of apoptosis in cancer 
cells. To test if tocotrienol-based derivatives also induce apoptosis, MCF-7 and MDA-
MB-231 cells were used for apoptosis analyses using the Annexin V/PI assay. As shown 
in Figure 2.3, tocotrienol derivatives induced apoptosis in a dose-dependent manner more 
effectively than -TEA.  
 
 
Figure 2.3. Comparison of apoptogenic activities of vitamin E derivatives.  
MCF-7 and MDA-MB-231 cells at 5X10
5
/well were seeded in 6-well plates. 
Cells were treated with 10, 20 or 40 µM of -TEA, -T3EA or -T3EA. Control 
cells were treated with vehicle at a final concentration of 0.1% ethanol. After 24 
hrs, cells were collected and labeled with Annexin V/PI. The labeled cells were 
analyzed by flow cytometer (FACSCalibur, BD Biosciences, CA). Data are 
depicted as mean  SD for three to six independent experiments (*significant 
difference from -T3EA or -T3EA treatments at the same concentration, 






























































2.3.3. Novel tocotrienol derivatives exhibited antiangiogenic properties in HUVECs. 
Studies using natural tocotrienols have demonstrated that angiogenesis is suppressed by 
tocotrienol treatment both in endothelial cells in cultures and in animal models (6). To 
test if the new compounds can modulate angiogenic activity of endothelial cells in culture, 
cell properties required for new vessel formation; namely, cell proliferation, migration 
and differentiation, were examined (81). First, apoptogenic effect of novel compounds on 
actively proliferating human umbilical vein endothelial cells (HUVECs) was tested using 
the Annexin V/PI assay. As shown in Figure 2.4.A, both tocotrienol derivatives induced 
strong apoptotic response in proliferating HUVECs, and the percentage of apoptotic cells 
was significantly higher than in -TEA treated cells. To test the effects of new compound 
on migration ability of endothelial cells at non-apoptotic concentrations, a wound healing 
assay was conducted as described by Staton et al. (81). While tocotrienols at 10 M 
exhibited little to moderate inhibitory effects on endothelial cell migration, tocotrienol 
derivatives at 2.5 M significantly inhibited the migration of endothelial cells (Figure 
2.4.B & C). Further analyses using in vitro tube formation assays showed that the novel 
compounds inhibited capillary-like tubule formation by endothelial cells at a non-
apoptotic concentration (Figure 2.4 D& E) and in a manner analogues to the migration 
inhibitory effect, higher concentrations (10 M) of natural tocotrienols (-T3 and -T3) 
exhibited only moderate to no inhibitory effects on tube formation. Taken together, these 
studies suggest improved chemotherapeutic potential for the tocotrienol-based derivatives 
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for these antiangiogenic parameters. Notably, -TEA did not inhibit HUVEC migration 
at 2.5 M or tube formation at 5 M (data not shown). 
2.3.4. Dietary administration of tocotrienol derivatives reduced tumor burden.  
Anti-tumorigenic properties of -T3EA or -T3EA in comparison to the parent 
compounds or -TEA supplemented in basal vitamin E (dl--tocopheryl acetate) diets 
were evaluated using the 66cl-4-GFP mouse mammary tumor syngeneic model as shown 
in Fig. 2.5. The average tumor growth rates of -TEA, -T3EA and -T3EA 
supplemented diet groups were significantly attenuated compared to the basal diet group 
(P<0.01). Among the natural tocotrienols, only -T3 significantly suppressed tumor 
growth while the -T3 group exhibited no tumor growth inhibitory effect. There was no 
difference observed in the tumor growth rate between -T3, -TEA, -T3EA and -
T3EA groups. The average body weight of mice at the beginning of the experiment was 
16.3 ± 0.2 grams and at the end of the experiment was 17.5 ± 0.3 grams. There was no 
significant difference in body weights among the groups (data not shown).  The average 
food consumption was 2.6  0.3 g, and no differences in the amount of food intake 
between groups was observed.  Immunohistochemical analyses of CD31 positive cells in 
tumor sections showed no difference between treatment groups and the basal control diet 







Figure 2.4. Antiangiogenic properties of tocotrienol derivatives in HUVECs. A, 
Cells were analyzed for apoptotic status using the Annexin V/PI assay after 24 hr 
treatments. Data are depicted as mean  SD for at least three independent 
experiments. B & C, Cells were analyzed for migration ability after treatment. 
Confluent cell monolayers were wounded and then treated with various 
concentrations of each compound for 15 hrs. Figures in B depict representative 
examples of cell migration into the wounded area. The graph in C represents the 
average percentage of the area covered by the treated cells in comparison to the area 
covered by the vehicle control treated cells (MeanSD, n=3). D & E, Cells were 
analyzed for the ability to form tubule-like structures. Cells were seeded in matrigel 
coated 96-well plates and treated with each compound. Control cells were treated 
with 0.1% ethanol. After 18 hrs, each well was photographed and the tube formation 
was evaluated by counting the number of tube nodes manually. The graph in E 
represents the average number of tubule nodes in treated samples compared to the 
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Figure 2.5. Average tumor volume (meanSE) over time of BALB/c mice 
bearing 66cl-4-GFP tumor cells. Each compound was incorporated into the 
adjusted vitamin E diet at a concentration of 250 mg of each compound/kg diet 
(0.025%). Tumor volume was measured every other day as described in 
Materials and Methods. *Significant difference from basal diet by one-way 









































2.3.5. Novel compounds were not retained in the liver as much as -TEA. 
Tissue concentration of each compound was analyzed using reverse-phase HPLC with 
fluorometric detection. Unfortunately, the novel compounds could only be detected in the 
liver. While -forms of each compound retained in the liver (-TEA, 55.18.7 nmol/g; 
-T3, 27.35.5 nmol/g; and -T3EA, 45.03.2 nmol/g), -T3 was retained at an 
approximately 8 times lower level than -T3 (3.81.0 nmol/g tissue) and -T3EA was 
undetectable as shown in Figure 2.6. These results suggest that -forms were either less 
incorporated into the liver or more rapidly metabolized by the liver in comparison to the 
-forms. While -T3EA was rapidly cleared from the body, -T3EA was highly retained 
in the liver.  
 
Figure 2.6. Concentrations of natural tocotrienols and vitamin E derivatives 
in the liver. The level of each compound was measured using reverse-phase 
HPLC with fluorometric detection at excitation and emission wavelength of 290 
and 330 nm respectively. Data are depicted as mean  SE (n=5). -T3EA was not 


































2.3.6. Lung metastases were not inhibited by either natural tocotrienols or vitamin E 
derivatives 
Micrometastatic foci in lung were counted by observing green fluorescent protein (GFP) 
tagged tumor cells under fluorescence microscope. A reduction in the number of 
micrometastatic foci was observed in all treatment groups compared to the basal diet 
group, but no significant difference was observed (Figure 2.7.A). Likewise, there was no 
reduction in average lung weight between groups, which suggests no suppressive effects 




Figure 2.7. Effects of tocotrienols and vitamin E derivatives on lung 
metastasis. A, GFP-labeled metastatic lung foci were counted using fluorescence 
microscopy. Data are depicted as mean  SE (n=10). B, Data represent average 










































Non-hydrolyzable, redox-silent modification of R,R,R--tocopherol confers pleiotropic 
anticancer properties: anti-proliferative, apoptosis-inducing, pro-survival inhibitory and 
anti-metastatic effects which are not observed in the parent compound (3). In an effort to 
generate stronger anticancer therapeutics, natural - and -tocotrienols were modified as 
redox-silent derivatives; namely -T3EA and -T3EA. Data presented here demonstrated 
that: 1) -T3EA and -T3EA reduced tumor cell viability and triggered a high degree of 
apoptosis in human breast cancer cells and mouse mammary tumor cells; 2) both -T3EA 
and -T3EA exhibited strong antiangiogenic activities which included apoptosis 
induction, migration inhibition, and tubule formation inhibition in human umbilical cord 
endothelial cells; 3) both apoptogenic activity and antiangiogenic properties of 
tocotrienol derivatives were significantly better than those of -TEA; 4) dietary delivery 
of -T3EA and -T3EA at 250 mg/kg diet significantly suppressed the growth of 66cl-4-
GFP mouse mammary tumor cells in a syngeneic mouse model; and 5)  both -T3 and its 
derivative exhibited low bioavailability.    
Modifications of natural vitamin Es aimed at improving proapoptotic activity of the 
parent compounds have been studied, especially after the discovery of proapoptotic and 
anti-neoplastic activities of -tocopherol succinate (-TOS) which has a hydrolysable  
succinic acid at the C6 position of the chroman head of -T (Figure 1.3). Birringer et al. 
(86) studied structure-function relation of vitamin E modifications, and found that 
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succinylation of the C6-phenolic group of natural tocopherols or -T3 via an ester bond 
significantly improved apoptogenic activities in various human cancer cell lines, such as 
T lymphoma, breast carcinoma, and neuroblastoma cells, although the improved efficacy 
was not observed in some types of prostate cancer cells (87). Data presented here showed 
that a non-hydrolysable acetic acid modification at the C6-phenolic ring of -T3, namely 
-T3EA showed improved efficacy of cell proliferation inhibition as well as apoptosis 
induction compared to the parent compound. In contrast, creation of -T3EA did not 
confer any additional anticancer properties to its parent compound, -T3, when treated 
using estrogen receptor positive or negative human breast cancer cells. Similar results 
were observed with a succinate derivative of -T3 in some types of prostate cancer cells 
(87), suggesting that the anticancer efficacy of each natural vitamin E compound or its 
corresponding derivative may vary depending on cellular context.  
One property of tocotrienols that distinguish them from tocopherols is antiangiogenic 
action which makes them a promising potential therapeutic agent for targeting specific 
cancers or various human diseases including age-related disorders (5, 88). In order to test 
if modification of tocotrienols can improve antiangiogenic activity of the parent 
compounds, several in vitro assays were conducted using HUVECs. Migration, 
proliferation, and differentiation of endothelial cells are critical elements of 
neovascularization (89). Both - and -T3EA induced apoptosis in actively proliferating 
HUVECs. These novel derivatives also inhibited migration and the differentiation of 
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HUVEC. Antiangiogenic effect of -TEA and -TOS observed in endothelial cells in 
cell culture showed high correlation with in vivo tumor suppression as well as reduction 
of tumor vasculature (90). In vitro antiangiogenic properties of - and -T3EA were 
markedly higher in comparison to either parent compounds or -TEA, suggesting the 
novel derivatives may be promising therapeutic agents to target diseases reliant on 
angiogenesis.  
Previous animal studies in our lab showed that dietary delivery of -TEA at 250 mg/kg 
diet significantly reduced tumor growth in a xenograft model of MDA-MB-231-GFP 
human breast cancer cells transplanted into immune compromised nude mice (18). Based 
on this study, 250 ppm of the novel tocotrienol derivatives or natural tocotrienols 
supplemented in diets were delivered to syngeneic 66cl-4-GFP tumor transplanted mice. 
This amount of vitamin E compound is equivalent to a daily intake of 134 mg of each 
compound in humans based on body surface area equivalency (84), since the amount of 
average diet consumed was 2.60.3 g/mouse/day (0.65 mg/mouse/day). Dietary delivery 
of -T3EA significantly inhibited tumor growth compared to the parent compound, but 
the effect was not better than -TEA. The tumor growth rate of -T3EA group was 
significantly different from the control group; however, the average tumor weight at the 
end of the experiment (Day 22) was not different from the average control tumors. In fact, 
-T3, the parent compound of -T3EA, displayed better tumor suppressive effect than its 
derivative. Although -TEA, -T3EA, and -T3 attenuated tumor growth rate, examining 
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tumor sections for CD31 as a biomarker for blood vessels showed that these compounds 
did not affect blood vessel formation in this tumor model. This suggests that at the 
supplemental dose used in these studies, -TEA- -T3EA- or -T3-anti-tumor effects 
were not correlated with anti-angiogenic actions. 
To address the discrepancy between cell culture and animal tumor efficacy studies, the 
tissue concentration of each compound was analyzed. Not surprisingly, -forms of 
natural vitamin E or derivatives were retained in the liver, whereas -T3 concentration in 
the liver was 8 fold lower than -T3. -T3EA was not detected in the liver, suggesting 
that -T3EA may not be taken up or retained by the tumor due to rapid metabolism in the 
liver. Although tumor levels of -T3EA were detected as high as -TEA, the tumor 
suppressive effect was not different from -TEA, implying that the degree of saturation 
in the fatty acid tail of vitamin E derivatives may not impact anti-tumor efficacy in vivo.  
Notably, our study showed that natural vitamin E form, -T3, exhibited significant 
attenuation in tumor growth; in fact as much as, -TEA at the supplemental dose (0.625 
mg/mouse/day) employed while -T3 did not.  This suggests that anticancer efficacy of 
-T3 is less effective than -T3 as previously suggested by Yu et al. based on the 
apoptogenic activity of each form of tocotrienol in human breast cancer cell lines (91) 
and by Constantinou et al. as reported for human prostate cancer cell lines in cell culture 
(87). A previous study by MacAnally et al. demonstrated that dietary delivery of -T3 at 
a dose of 250 mg/kg diet reduced the mean weight of melanomas by 50% compared to 
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the control group in a syngeneic mouse model (33). In our study, -T3 at a dose of 250 
mg/kg diet reduced mammary tumor burden by 35%. Although we didn‟t test -T3 in 
vivo, it is possible that -T3 might exhibit a better efficacy than -T3 in vivo, since cell 
proliferation suppressive effects of -T3 is reported as the most potent of all eight natural 
forms of vitamin E in prostate cancer cells in cell culture (87).  
In summary, these findings demonstrate that redox-silent modification of both -
tocopherol and tocotrienols function effectively as anticancer agents. The rapid 
metabolism of -form of natural tocotrienol or its derivative limits in vivo application. 
Further studies are needed to understand structure-function relationships among natural 
or synthetic vitamin Es and their derivatives, which will aid design of various vitamin E 
derivatives with improved bioavailability. Identifying the mechanisms of anticancer 
actions of different forms of vitamin E and their derivatives is another critical area to be 






Chapter 3. Tocotrienols induce apoptosis in breast cancer cell lines via an 
endoplasmic reticulum stress dependent increase in extrinsic death receptor 
signaling  
Tocotrienols are naturally occurring forms of vitamin E and known to possess anti-
proliferative and apoptosis-inducing properties. This study focused on investigating 
anticancer effects of tocotrienols and the mechanisms of apoptosis induction by 
tocotrienols in vivo and in vitro. Dietary delivery of -tocotrienol (-T3) suppressed 
tumor growth in a syngeneic implantation mouse mammary cancer model by inhibiting 
cell proliferation and inducing apoptosis. In cell culture studies, -T3 inhibited colony 
formation of a mouse mammary cancer cell line and human breast cancer cell lines. The 
anti-proliferative effect of tocotrienols was correlated with an increase in apoptosis based 
on Annexin V assessment. Treatment of human MDA-MB-231 and MCF-7 cells with -
T3 induced cleavage of caspases-8, -9 and -3 as well as PARP. Additional analyses 
showed that -T3 activated c-Jun NH2-terminal kinase (JNK) and p38 MAPK, and 
upregulated death receptor 5 (DR5) and C/EBP homologous protein (CHOP), a 
biomarker of endoplasmic reticulum (ER) stress. Silencing either JNK or p38 MAPK 
reduced the increase in DR5 and CHOP and partially blocked -T3-induced apoptosis. 
Both DR5 and CHOP upregulation were required for -T3-induced apoptosis, and DR5 
was transcriptionally regulated by CHOP after -T3 treatment. Moreover, -T3 increased 
the level of other ER stress markers. Taken together, these results suggest that 
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upregulation of DR5 by -T3 treatment is dependent on JNK and p38 MAPK activation 
which is mediated by ER-stress.  
 
3.1. Introduction 
Tocotrienols are highly enriched in palm oil and also found in the seed endosperm of 
monocots such as wheat, rice, barley, oat and rye (92). The anti-proliferative and 
apoptosis-inducing properties of a tocotrienol-rich fraction (TRF) extracted from palm oil 
or individual tocotrienol forms are well documented in cell culture studies using human 
breast cancer cells or mouse mammary cancer cells (reviewed by (20)). Studies 
evaluating tocotrienols as an anticancer agent also include other types of human cancers, 
such as colorectal cancer, gastric adenocarcinoma, liver cancer, lung carcinoma, 
pancreatic cancer, and prostate cancer (21-26).   
Possible intracellular mechanisms of tocotrienol-mediated growth inhibition or apoptosis 
induction have been proposed. In neoplastic murine mammary epithelial cells, -
tocotrienol (-T3) antagonizes phosphatidyl inositol-3 kinase (PI-3K)/Akt and nuclear 
factor-B (NF-B) signaling pathways, and also induces caspase 8 activation (28, 29). In 
human breast cancer cells, -tocotrienol-triggered apoptosis involves upregulation of 
transforming growth factor- receptor II (TGF-RII) and is mediated by TGF--, 
Fas/CD95-, and c-Jun N-terminal kinase (JNK)-signaling pathways (30). -Tocotrienol 
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also induces G0/G1 cell cycle arrest by reducing phosphorylation of retinoblastoma 
protein (Rb) and the loss of cyclin D1/cyclin dependent kinase 4 (CDK4) expression (31). 
Several in vivo studies also support the anticancer effect of tocotrienols alone or together 
with statins, the competitive inhibitors of 3-hydroxyl-3-methylglutaryl coenzyme A 
(HMG CoA) reductase (32, 33). Another unique property of tocotrienols is inhibition of 
angiogenesis which is believed to be the major therapeutic target against various human 
disorders including cancer, diabetic retinopathy, and rheumatoid arthritis (6, 93). 
Additionally, highly malignant mammary epithelial cells are more sensitive to anti-
proliferative and apoptotic effects of tocotrienols; whereas, preneoplastic cells are less 
sensitive to the treatment effects (27). Because of the aforementioned advantages to 
human health, tocotrienols have gained substantial attention; however, a more complete 
understanding of their anticancer mechanisms of action needs to be elucidated.  
The unfolded protein response (UPR) is an evolutionary conserved response triggered by 
disturbances in intracellular calcium homeostasis, protein secretion, redox regulation or 
lipid biosynthesis in the endoplasmic reticulum (ER) (52). The accumulation of unfolded 
protein in the ER initially induces expression of genes that restore homeostasis by 
enhancing protein folding capacity. ER stress also activates signal transduction pathways 
associated with cellular stresses including activation of mitogen-activated protein kinases 
(MAPKs), JNK and p38 MAPKs (53). If the UPR is persistent or excessive, the cell 
eventually undergoes programmed cell death, typically apoptosis (52). The C/EBP 
homologous protein (CHOP), also known as growth arrest- and DNA damage-inducible 
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gene 153 (GADD153), is a transcription factor that is upregulated at multiple levels by 
ER stress. CHOP directly regulates target genes including Bcl-2, GADD34 and ERO 
whose products mediate ER stress induced apoptosis (60). ER stress can sensitize cells to 
tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) signaling by 
upregulation of death receptor-5 (DR5) which enables the recruitment of adaptor proteins 
to trigger apoptosis upon ligand binding (94). In recent years, various cytotoxic agents 
used in cancer therapy that target different biological pathways have been reported to 
induce ER stress-mediated apoptosis. Examples include proteasome inhibitors, 
triterpenoid derivative, proteasome-proliferator activated receptor (PPAR) ligands, and 
ruthenium-derived organometallic compounds (53, 95-97).  
Here, we investigated mechanisms involved in tocotrienol anticancer activities using a 
syngeneic mouse mammary tumor model and human breast cancer cell lines in cell 
culture. Dietary delivery of -T3 inhibited 66cl-4-GFP tumor growth in the mouse model 
by inhibiting cell proliferation and inducing apoptosis. Cell culture studies showed that 
anti-proliferative effects of tocotrienols are highly correlated with increases in apoptosis. 
In vitro analyses showed that tocotrienols trigger apoptosis via ER stress which produces 
an upregulation of DR5 in a CHOP dependent manner and the activation of JNK and p38 
MAPK.   
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3.2 Materials and methods 
3.2.1. Cell culture and reagents 
The source and culture conditions for 66cl-4-GFP murine mammary tumor cells were 
previously described (79).  MDA-MB-231 and MCF-7 human breast cancer cells were 
cultured and maintained in MEM medium as previously described (18). MDA-MB-468 
cells were maintained in RPMI 1640 medium and T47D cells were maintained in DMEM 
high glucose medium. All human breast cancer cells were obtained from the American 
Type Culture Collection (ATCC). All maintenance media were supplemented with 10% 
fetal bovine serum (HyClone Laboratories, Logan, UT), 100 U/ml penicillin, and 100 
mg/ml streptomycin. For all treatments, FBS was reduced to 2% to better mimic in vivo 
low serum exposure of these cell types. -, -, and -tocotrienols were kindly provided by 
the Malaysian Palm Oil Board (Kuala Lumpur, Malaysia) and dissolved in ethanol. 
Salubrinal was purchased from EMD Biosciences (San Diego, CA) and desipramine, an 
ASMase inhibitor was purchased from Sigma-Aldrich (St. Louis, MO). Salubrinal and 
desipramine were dissolved in dimethyl sulfoxide (DMSO).  
3.2.2. Immunohistochemistry analyses of tumor sections 
Primary tumors from 5 individual mice fed with basal diet (vitamin E adjusted diet), -
T3 or -T3 containing diets (250 mg/kg diet) for 21 days were collected at the time of 
animal sacrifice and fixed in 10% formalin. Samples were processed for 
immunohistochemical analyses by the Histological & Tissue Processing Facility Core 3 
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at the University of Texas M.D. Anderson Cancer Center-Science Park Research 
Division (Smithville, TX) as previously describe (41, 79). Briefly, deparaffinized tumor 
sections (5 m) were examined using antibody against Ki-67, a biomarker for 
determining active cell division and  terminal deoxynucleotidyl transferase-mediated nick 
end labeling (TUNEL) assay for determining number of apoptotic cells. For Ki-67 
analyses, three randomly chosen microscopic fields (X100) per tumor were scored. For 
TUNEL analyses, at least ten randomly chosen microscopic fields (X400) were scored.  
3.2.3. Clonogenic assay of cells in vitro (colony formation assay) 
Effect of tocotrienols on capacity of tumor cells to undergo unlimited division was 
assessed using a standard clonogenic assay (98). Cells were seeded in 6-well plates at 300 
cells per well for 66cl-4-GFP and MCF-7 cells, or 200 cells per well for MDA-MB-231 
cells. After 48 hrs, cells were treated with 1.25, 2.5 or 5 μM of -T3, -T3 or -T3.  
Control cells were treated with the vehicle (final concentration = 0.02% ethanol). After 2 
weeks, cells were fixed with 10% formalin followed by staining with 2% (w/v) crystal 
violet in H2O. Colonies containing more than 50 cells were scored.  
3.2.4. Cell proliferation assay (MTS assay) 
Effect of tocotrienols on cell proliferation was assessed using CellTiter 96®  AQueous 
Non-Radioactive Cell Proliferation Assay (Promega Corp., Madison, WI). MDA-MB-
231 or MCF-7 cells at 5X10
3
/well and 66cl-4 cells at 10
4
/well were seeded in 96-well 
plates. Cells were treated with a range of concentrations from 5 to 40 µM of -T3, -T3 
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or -T3. Control cells were treated with the vehicle (ethanol) at a final concentration of 
0.1%. After 24 hrs, viable cell number was measured following manufacturer‟s 
instructions. The percentage of viable cells at each concentration was calculated by 
dividing color absorbance (A490) of treated cells by that of control cells. The half 
maximal inhibitory concentration (IC50) was determined using Graphpad Prism software.  
3.2.5. Evaluation of apoptosis (Annexin V assay) 
Number of apoptotic cells after treatment was evaluated using Annexin V- Fluorescein 
isothiocyanate (FITC)/Propidium iodide (PI) assay or Annexin V-Phycoerythrin (PE) 
assay as previously described (17). Briefly, cells were collected at various time points 
and resuspended in Annexin V binding buffer (10 mM HEPES (pH 7.4), 150 mM NaCl, 
5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2). Human breast cancer cells were incubated 
with Annexin V-FITC (Invitrogen, CA) for 8 min at room temperature, and then 
suspended in PI solution (50 ng/mL in PBS). For 66cl-4-GFP cells, Annexin V-PE 
(Invitrogen, CA) was added to the cells following 8 min incubation. Fluorescence was 
measured using flow cytometry (FACSCalibur, BD Biosciences, CA) and the data were 
analyzed using CellQuest software (FACSCalibur, BD Biosciences, San Jose, CA). The 
half maximal effective concentration inducing apoptosis in 50% of the cell population 




3.2.6. Western blot analyses 
Whole cell lysates were used to analyze protein expression levels as previously described 
(99). Antibodies to activating transcription factor-4 (ATF4), caspase-3, CHOP, c-Jun, 
DR4, JNK 1/2, Histone H1, p38 MAPK, phospho-c-Jun and poly (ADP-ribose) 
polymerase (PARP) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Antibodies to caspase-8, caspase-9, DR5, phospho-JNK 1/2, phospho-p38 MAPK were 
purchased from Cell Signaling Technology (Beverly, MA). Antibody to GAPDH was 
produced in house. Secondary antibodies conjugated with horseradish peroxidase 
included goat anti-rabbit and rabbit anti mouse IgG (Jackson Immunoresearch, Rockford, 
IL); and bovine anti-goat IgG (Santa Cruz Biotechnology). To quantitate the expression 
level, densitometric analyses were conducted using ImageJ software.  
3.2.7. Gene silencing using siRNA 
Small interfering RNAs targeting CHOP, DR5, JNK1/2, p38 MAPK or acid 
sphingomyelinase (ASMase) were purchased from Ambion (Austin, TX). Transient 
transfection with siRNAs was conducted as described elsewhere (16). A scrambled 
siRNA (Ambion) that targets no known mouse, rat, or human gene was used as a non-





3.2.8. Chromatin immunoprecipitation assay (ChIP assay) 
MDA-MB-231 cells were treated with 30 M of -T3 or vehicle (0.08% ethanol) for 15 
hrs. Formaldehyde was added to the cell medium at a final concentration of 1% for 12 
min followed by the addition of glycine (0.125M) to stop the cross-linking. Collected 
cells were prepared for the ChIP assay as described by Nelson et al. (100). The same 
CHOP antibody (B-3, sc-7351) used for the western blot analyses was used for 
immunoprecipitation. As an isotype control, normal mouse IgG1 purchased from Santa 
Cruz Biotechnology was used. To detect CHOP binding sites in the DR5 promoter region, 
polymerase chain reaction (PCR) was conducted using the primers as described by 
Adbelrahim et al. (101).   
3.2.9. Nuclear and cytoplasmic fractionation  
Nuclear localization of activating transcription factor (ATF4), a transcription factor 
translationally activated and localized in nuclei under ER stress was analyzed (102). 
Cytoplasmic and nuclear fractions were prepared as described by Bijur et al. (103). 
Briefly, cells were collected after trypsinization, washed twice with phosphate buffered 
saline (PBS) and lysed with lysis buffer (10 mM Tris, pH 7.5, 10 mM NaCl, 3 mM 
MgCl2, 0.05% Nonidet P-40, 1 mM EGTA, protease inhibitor cocktail). Whole cell 
lysates were centrifuged at 2700 xg for 10 min at 4C. The resulting pellet contained 
nuclear fraction and the supernatant containing the cytosol was centrifuged again at 
20,000 xg for 15 min at 4C. Then, the supernatant was retained as the cytosolic fraction. 
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The nuclear pellet was washed twice with wash buffer (10 mM PIPES, pH 6.8, 300 mM 
sucrose, 3 mM MgCl2, 1 mM EGTA, 25 mM NaCl, protease inhibitor cocktail). After 
final wash, the resuspended pellet was layered over a cushion of 1 ml sucrose buffer (1 M 
sucrose and protease inhibitor cocktail) and centrifuged at 2700 xg for 10 min at 4C. 
The supernatant containing cellular debris was discarded and the pellet containing nuclei 
was washed once with lysis buffer. The pellet was lysed using RIPA buffer (50 mM Tris-
HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 
protease inhibitors). Protein concentrations in the cytosolic and nuclear extracts were 
determined using Coomassie Brilliant Blue G-250 dye (Bio-rad, Hercules CA).  
3.2.10. Quantitative real time-PCR (qRT-PCR) and reverse transcriptase PCR (RT-
PCR) analyses of DR5, GRP78 and X-box binding protein (XBP-1) splice variants. 
Status of messenger RNA levels for GRP78 and XBP-1 mRNA splice variants were 
assessed. Cells were collected as various time points and total RNA was purified using 
RNeasy mini kit following manufacturer‟s instructions (Qiagen Inc., Valencia, CA). Two 
g of RNA from each sample was used for the reverse transcription reaction using 
SuperScript First Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA). 
Amplification of GRP78 was analyzed by reverse transcriptase PCR. The primers used to 
detect GRP78 were 5‟-GATAATCAACCAACTGTTAC-3‟ (forward) and 5‟-
GTATCCTCTTCACCAGTTGG-3‟ (reverse) as described by Wang et al (104); and to 
detect GAPDH were 5‟-ACCACAGTCCATGCCATCAC-3‟ (forward) and 5‟- 
65 
 
TCCACCACCCTGTTGCTGTA-3‟ (reverse). The splicing of Xbp-1 mRNA serves as an 
indicator of ER stress response (105). The detection of Xbp-1 splice variants was 
conducted as described by Marciniak et al. (60). To distinguish the 448 bp spliced band 
from the 473 bp unspliced form, PCR products were digested with Pst I which cuts only 
in the unspliced cDNA and gives 290 and 183 bp fragments (60). For quantitative 
analysis of DR5 mRNA expression, qRT-PCR was performed using SYBR Green PCR 
Master Mix (Applied Biosystems Inc., Foster City, CA) following manufacturer‟s 
instructions. The primers used to detect DR5 were 5‟-TGACTCATCTCAGAAATGTC-
AATTCTTA-3‟ (forward) and 5‟-GGACACAAGAAGAAAACCTTAATG-3‟ (reverse)‟; 
and to detect GAPDH were 5‟-CCTGTTCGACAGTCAGCCG-3‟ (forward) and 5‟- 
CGACCAAATCCGTTGACTCC-3‟ (reverse). Changes in gene expression were 
analyzed by comparative CT method following ABI PRISM 7700 Sequence Detection 
System User Bulletin #2: Relative Quantitation of Gene Expression (P/N4303859). 
GAPDH was used for normalization of DR5 expression.  
3.2.11. Statistical analysis 
Differences in number of TUNEL and Ki-67 positive cells were determined with t-test 
(two-tailed, unpaired) using Prism software version 4.0 (Graphpad, San Diego, CA). A 
level of P<0.05 was regarded as statistically significant. Student t-test (two-tailed, 





3.3.1. Dietary administration of -T3 reduces murine mammary tumor burden and 
in vivo cell proliferation.  
The anti-tumor property of dietary -T3 or -T3 in comparison to the basal vitamin E (dl-
-tocopheryl acetate) diet was evaluated as described in Chapter 2 (Fig. 2.5). The 
average tumor volume of the -T3 diet group was significantly smaller than the basal diet 
group (P<0.001), while the -T3 diet group exhibited no tumor growth inhibitory effect. 
To study the mechanism of antitumor effects of -T3, immunohistochemical analyses of 
tumor sections for Ki-67 and TUNEL labeling were analyzed as shown in Figure 3.1. 
Tumors from the -T3 diet group had 55% less Ki-67- positive cells and 386% more 
TUNEL positive cells compared to the basal diet group (P=0.026 and P=0.077, 
respectively). Tumors from the -T3 diet group had 29% less Ki-67 positive cells and 
141% more TUNEL positive cells than the basal diet group (P=0.093 and P=0.340, 
respectively). All together, these results indicate that -T3 exhibits anti-tumor activity by 
inhibiting tumor cell proliferation and also inducing apoptosis. -T3 did not exhibit 





Figure 3.1.  -T3 inhibits cell proliferation and enhances apoptosis in vivo. A, 
Immunohistochemical staining of tumors (n=5) for cell proliferation (Ki-67). 
Three randomly chosen microscopic fields (X100) per tumor section were scored 
(mean SE). **Significant difference from control diet by t-test (P<0.05). B, 
Immunohistochemical staining of tumors (n=5) for apoptosis (TUNEL staining). 
Ten randomly chosen microscopic fields (X400) were scored (meanSE).  
 
3.3.2. T3s inhibit colony formation and cell proliferation by inducing apoptosis in 
murine mammary tumor cells and human breast cancer cells in culture. 
To compare the anti-cancer activity of different tocotrienol forms in murine mammary 
cancer cells and human breast cancer cell lines, colony formation assays were conducted 
using human estrogen receptor-negative (MDA-MB-231) and positive (MCF-7) breast 
cancer cells along with 66cl-4-GFP cells (Figure. 3.2). In all three cell lines, -T3 showed 
the best efficacy and -T3 exhibited the least efficacy. Although -T3 did not reduce 
tumor burden in vivo, it did show inhibitory effects on colony formation in all three cell 






































































To investigate how the inhibitory effects of tocotrienols were being mediated, analyses of 
cell proliferation and apoptosis were conducted (Table 3.1). Both -T3 and -T3 strongly 
inhibited cell proliferation and induced apoptosis in a dose dependent manner while -T3 
did not show any anti-proliferative or apoptogenic effects on any of the cell lines after 24 
hrs of treatment. Apoptosis analyses using the Annexin V assay revealed that the anti-
proliferative effects of -T3 and -T3 were highly correlated with the induction of 








Figure 3.2. Inhibitory effects of tocotrienols on colony formation of murine 
mammary tumor cells and human breast cancer cells. Cells were seeded in 6-
well plates (200 cells/well for MDA-MB-231 cells; 300 cells for the other cell 
types). After 48 hrs, cells were treated with 1.25, 2.5 and 5 μM of -T3, -T3 or 
-T3. Control cells were treated with vehicle at a final concentration of 0.02% 
ethanol. After 2 weeks, cells were fixed with 10% formalin and stained with 2% 
crystal violet. Colonies containing at least 50 cells were scored. A, Colony 
formation data are depicted as percentage of control (meanSD) for murine 66cl-
4-GFP (top), human MDA-MB-231 (middle) and human MCF-7 cells (bottom). 
B,  Representative examples of colonies produced by 66cl-4 GFP cells treated 




-T3, 5.0 M-T3, 2.5 M
Vehicle -T3, 5.0 M-T3, 2.5 M












































































































Table 2. Comparison of 50% effective anti-proliferative concentration (IC50) and 
apoptotic concentration (EC50) of tocotrienols on mouse mammary tumor cells 




















 N.D. N.D. N.D. N.D. 
-T3 20.6 34.6 27.5 27.7 22.2 21.6 
-T3 10.5 12.3 12.0 20.0 17.0 12.1 
1
 Cells were treated for 24 hrs with concentrations of 5, 10, 20, 40 or 80 M of each tocotrienol 
compound. Cell proliferation was measured using CellTiter 96®  AQueous Non-Radioactive Cell 
Proliferation Assay (n=6). IC50 designates concentration producing 50% inhibition of cell 
proliferation.  
2 
Cells were treated for 24 hrs with concentrations of 10, 20, 30 or 40 M of each tocotrienol 
compound. Apoptotic cell population was analyzed using Annexin V/PI assay (n=3). EC50 
designates the concentration causing 50% apoptosis. 
3 
Not determined: -T3 failed to induce inhibition of cell proliferation or apoptosis at the highest 






3.3.3. -T3 induces caspase cleavage and upregulation of JNK/c-Jun 
phosphorylation; as well as, increased expression of death receptor 5 (DR5).  
Caspase cleavage after -T3 treatment of human breast cancer cells was assessed using 
western blot analyses. As shown in Figure. 3.3, cleaved forms of caspase-8 and -9; as 
well as PARP were observed after -T3 treatment in a dose dependent manner in both 
MDA-MB-231 and MCF-7 cells. Caspase 3 cleavage was observed in MDA-MB-231 
cells but not in caspase 3-deficient MCF-7 cells. Similar data were observed when T47D 
and MDA-MB-468 were examined (data not shown), demonstrating that these responses 
are not cell type specific. Since the apoptotic response induced by -T3 was associated 
with cleavage of caspase 8, an initiator caspase for extrinsic death receptor signaling, 
next death receptors (DR) expression was examined. DR5 (L/S) protein was increased in 
a dose dependent manner in all four cell lines, but DR4 protein level was increased only 
in MDA-MB-231 and T47D cells but not in MCF-7 and MDA-MB-468 cells (Fig. 3.3.B, 
data not shown for T47D and MDA-MB-468). Notably, phosphorylation of JNK 1/2 and 
both protein levels and phosphorylation status of c-Jun were increased as DR5 expression 










Figure 3.3. Caspases and PARP were cleaved, JNK and c-Jun were activated, 
and DR5 expression was increased after -T3 treatment in a dose-dependent 
manner. Cells at 2.5X10
6
/plate were seeded in 100 mm plates. One day later, 
cells were treated with 10, 20, 30 or 40 µM of -T3. Control cells were treated 
with the vehicle at a final concentration of 0.08% ethanol. After 18 to 24 hrs, 
cells were collected and analyzed to detect the expression of pro-and cleaved-
forms of caspase 8, caspase 9, caspase 3, and PARP (A); and p-JNK, JNK, p-
cJun, cJun, DR5 (L/S) and DR4 (B) by Western blot analyses. Arrow heads in (A) 
indicate cleaved forms of PARP and caspases. GAPDH was used as a loading 
control for densitometric analyses. Numbers below p-JNK 1 and 2 represent fold 
change of each phosphorylated form to total JNK 1 and 2 levels respectively 
compared to the vehicle control. The other numbers represent the fold changes 
compared to the vehicle control. Data are representative of at least three 
independent experiments.  
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1.0 0.91.4 1.4 1.1
1.0 14.21.5 1.7 4.2
1.0 6.81.0 1.4 6.9
1.0 1.80.9 1.0 0.8
1.0 23.51.4 2.3 4.41.0 5.50.7 1.8 2.2
1.0 14.11.3 2.3 8.8 1.0 142.220.5 54.6 59.3
1.0 1.61.5 2.2 1.31.0 7.50.7 0.7 7.6
1.0 5.02.5 4.4 2.61.0 9.90.9 1.1 8.2
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3.3.4. -T3 induced apoptosis is mediated by CCAAT/enhancer binding protein 
(C/EBP) homologous protein (CHOP)-mediated DR5 upregulation in human breast 
cancer cells. 
Assessment of DR5 protein and mRNA expression at various time intervals following -
T3 treatment showed time-dependent increases at both mRNA and protein levels (Figure 
3.4.A & B). To address if DR5 was necessary for -T3-induced apoptosis, DR5-specific 
siRNA was used to knockdown DR5. Data in Figure 3.4.C show that siRNA to DR5 
significantly blocked -T3 induced apoptosis, substantiating that DR5 plays a critical role 
in -T3-induced apoptosis. Data in Figure 3.4.D confirm the effectiveness of the 
knockdown in blocking -T3-induced apoptosis. Since it has been reported that DR5 can 
be transcriptionally activated by CHOP, we analyzed CHOP expression. As shown in 
Figure 3.5.A, the level of CHOP expression was increased in a time dependent manner. 
Silencing CHOP using siRNA not only inhibited apoptosis (Figure 3.5.B) but also 
partially suppressed the upregulation of DR5 after -T3 treatment (Figure 3.5.C). To 
determine whether DR5 transcription was directly regulated by CHOP, a ChIP assay was 
conducted. This assay showed that -T3 treatment enhanced the binding of CHOP to the 
DR5 promoter (Figure 3.5.D). Taken together, these data strongly suggest that CHOP is 
necessary for -T3-induction of apoptosis and that -T3‟s ability to increase DR5 protein 





Figure 3.4. Protein and mRNA levels of DR5 were increased in a time-
dependent manner after -T3 treatment, and siRNA against DR5 partially 
blocked -T3 induced apoptosis. A & B, Cells were treated with 40 µM of -T3 
for indicated time points. Control cells were treated with the vehicle at a final 
concentration of 0.08% ethanol. Cells were collected and analyzed to detect the 
expression of DR5 by qRT-PCR (A); as well as, by western blot (B). Graphs in A 
represent fold increases in DR5 mRNA level (meanSD) analyzed by qRT-PCR 
using comparative CT method as described in 3.2. Materials and Methods. 
Amplification of GAPDH mRNA was used as an endogenous control for the 
normalization. Data are representative of three independent experiments. 
*Statistically different from the vehicle control (P<0.05, t-test). The numbers in 
B represent the fold changes compared to the vehicle control. GAPDH was used 
as a loading control for densitometric analyses. C & D, MDA-MB-231 cells at 
2.0X10
6
/plate were seeded in 100 mm plates. Cells were transfected with control 
or DR5 siRNA for 48 hrs. Then cells were treated with 30 M of -T3 for 18 hrs. 
Cells were collected and analyzed for annexin-V labeling (C) and western blot (D) 
to characterize the apoptotic response (MeanSD). Data are representative of at 
least three independent experiments. **Statistically different from the control 
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Figure 3.5. -T3 treatment increased CHOP expression in a time-dependent 
manner. Silencing CHOP partially blocked -T3’s ability to induce apoptosis 
and increase DR5 protein levels. A, Cells were treated with 40 µM of -T3 for 
indicated time points. Control cells were treated with the vehicle for 16 hrs at a 
final concentration of 0.08% ethanol. Cells were collected and analyzed to detect 
the expression of CHOP by western blot. GAPDH was used as a loading control. 
B & C, MDA-MB-231 cells at 2.0X10
6
/plate were seeded in 100 mm plates. 
Cells were transfected with control, CHOP or DR5 siRNA for 48 hrs. Then cells 
were treated with 30 M of -T3 for 18 hrs. Cells were collected and analyzed 
for annexin-V labeling (B) and by western blot assay (C) to characterize the 
apoptotic response (MeanSD). *Statistically different from the control siRNA + 
-T3 (P<0.05, t-test). D, Direct binding of CHOP to the promoter region of DR5 
was analyzed using the ChIP assay. MDA-MB-231 cells were treated with -T3 
(30 M) for 15 hrs and then analyzed by ChIP assay as described in 3.2. 
Materials and Methods. IgG served as a non-specific control in the 
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3.3.5. Activation of JNK and p38 MAPK are required for the expression of CHOP 
and DR5, which play a critical role in -T3 induced apoptosis. 
To further clarify the signaling pathways triggered by -T3, activation of JNK and p38 
MAPK was analyzed. Data showed that both JNK and p38 MAPK were phosphorylated 
in both cell lines by 4 to 8 hrs following treatment with 40 M -T3, and their activation 
proceeded increases in DR5 and CHOP protein levels (Figure 3.6.A). These observations 
raised the possibility that both JNK and p38 MAPK were playing a role in -T3-induced 
apoptosis. Silencing either JNK or p38 MAPK partially blocked apoptosis induced by -
T3 (Figure 3.6.B & C). Interestingly, knockdown of either JNK or p38 MAPK produced 
decreases in DR5 and CHOP protein levels. These results suggest that JNK and p38 
MAPK activation is required for the apoptotic response; as well as, is involved in the 
increases in DR5 and CHOP expression. Next, we examined if the activation of JNK and 
p38 MAPK after -T3 treatment is mediated by ER stress by using a chemical inhibitor, 
salubrinal, which specifically blocks ER stress induced apoptosis (106). Salubrinal in 
combination with -T3 protected MDA-MB-231 and MCF-7 cells from -T3-induced 
cleavage of caspase-8 and -9; as well as, PARP, suggesting that inhibition of ER stress 
can partially block -T3-mediated apoptosis (Figure 3.7.A & B). Salubrinal in 
combination with -T3 also partially blocked increases in phosphorylation status of JNK 
and p38 MAPK. These data suggest that the activation of JNK and p38 MAPK after -T3 




Figure 3.6. JNK and p38 MAPK were phopsphorylated by -T3 treatment 
and silencing JNK or p38 MAPK partially blocked -T3-induced apoptosis. 
A, Cells were treated with 40 µM of -T3 for indicated time points. Control cells 
were treated with the vehicle for 16 hrs at a final concentration of 0.08% ethanol. 
Cells were collected and analyzed to detect the expression of each protein by 
Western blot. Numbers below p-JNK 1/2 and p38 represent fold changes of p-
JNK 1/2 and p-p38 MAPK to total JNK and p38 MAPK level compared to the 
vehicle control. The numbers below DR5 and CHOP represent the fold changes 
compared to the vehicle control. Data are representative of three independent 
experiments. B & C, MDA-MB-231 cells at 2.0X10
6
/plate were seeded in 100 
mm plates. Cells were transfected with control, JNK 1/2 or p38 siRNA for 48 hrs. 
Then cells were treated with 30 M of -T3 for 18 hrs. Cells were collected and 
analyzed by annexin V labeling (B) and western blot (C) for apoptotic response. 
Data are representative of 2 to 4 independent experiments. *Statistical difference 
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1.0 1.70.7 1.1 1.51.0 6.21.4 1.9 3.8























Figure 3.7.  -T3 induced apoptosis was attenuated by ER stress inhibitor. A 
& B, MDA-MB-231 and MCF-7 cells at 2.5X10
6
/plate were seeded in 100 mm 
plates. Cells were treated with DMSO or 65 µM of salubrinal combined with 30 
M of -T3 or ethanol (0.08%) for 18 hrs. Cells were collected and analyzed to 
detect the expression of each protein. GAPDH was used as a loading control. 
Cells were collected and analyzed by Western blot (A) and annexin V labeling 
(B). Data are representative of at least 3 independent experiments. *Statistical 
















































































3.3.6. ER-stress is coupled with -T3-induced apoptosis in human breast cancer cells. 
To further examine the involvement of ER stress in -T3 induced apoptosis, we analyzed 
several ER stress markers, ATF4, XBP-1 splice variant and GRP78. Nuclear and 
cytoplasmic fractionation showed that ATF4 was localized to the nucleus as early as 4 hrs, 
and elevated levels of ATF4 in comparison to vehicle control were observed at all time 
points examined following -T3 treatment (Figure 3.8.A). Likewise, CHOP was also 
elevated in the nuclear fraction from 8 hrs after -T3 treatment. XBP-1 is another 
downstream effector and transcription factor activated upon ER stress. The splicing of 
XBP-1 mRNA yields its bZIP and transactivation domain (61). After 4 to 8 hrs of -T3 
treatment, XBP-1 mRNA splicing was observed in both MDA-MB-231 and MCF-7 cells 
(Figure 3.8.B). GRP78, also known as BiP is an ER chaperon and senses the onset of the 
unfolded protein response (UPR). As shown in Figure 3.8.B, GRP78 expression was 
elevated at both mRNA and protein levels at 8 hrs of -T3 treatment. In order to figure 
out if ER stress caused by -T3 is a general phenomenon shared by other forms of 
tocotrienols, we treated MDA-MB-231 cells with -T3 or tocotrienol rich fraction (TRF) 
and analyzed the expression level of CHOP and DR5. As shown in Figure 3.8.C, both -
T3 and TRF produced DR5 and CHOP upregulation; as well as, PARP cleavage. In 
comparison to -T3 data, these data indicate that the  form or a mixture of T3s may 
activate the same apoptotic pathways as -T3; namely induction of ER stress and 




Figure 3.8. ER stress was coupled with the treatment of -T3. -T3 and TRF 
upregulated GRP78, CHOP and DR5. A, ATF4 expression was increased both in the 
cytoplasmic and nuclear fractions. MDA-MB-231 cells at 2.5X10
6
/plate were seeded in 
100 mm plates. Cells were treated with 40 M of -T3 for indicated time points. Cells 
were collected and the nuclear and cytoplasmic fractions were isolated. GAPDH and 
histone H1 were used for cytoplasmic and nuclear markers as well as the loading controls, 
respectively. B, Xbp-1 mRNA was spliced and GRP78 was upregulated after -T3 
treatment. MDA-MB-231 and MCF-7 cells at 2.5X10
6
/plate were seeded in 100 mm 
plates. Cells were treated with 40 M of -T3 for indicated time points. Cells were 
collected and analyzed by RT-PCR. PCR products were incubated with PstI. Only the 
unspliced form of Xbp-1 is cut by PstI which produces 290 and 183 bp fragments. The 
expression of GRP78 was analyzed by RT-PCR and Western blot analyses. The arrow 
head indicates the protein band specific for GRP78. C, MDA-MB-231 cells at 
2.5X10
6
/plate were seeded in 100 mm plates. One day later, cells were treated with 
indicated concentrations of -T3 or tocotrienol-rich fraction (TRF). Control cells were 
treated with the vehicle at a final concentration of 0.08% ethanol. After 16 hrs, cells were 
collected and analyzed to detect the expression of GRP78, CHOP and DR5 by Western 
blot analyses. Arrow heads indicate cleaved form of PARP and GRP78 specific band. 
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3.3.7. Inhibition of acid sphingomyelinase (ASMase) reduced apoptosis as well as 
ER-stress-induced increases of caspase 8 cleavage, CHOP and DR5 expression.  
To identify the factor that triggers ER stress after -T3 treatment, the function of ASMase, 
an enzyme that is known to breakdown sphingomyelin in the membrane thereby releasing 
the second messenger ceramide, was examined. As shown in Figure 3.9.A, desipramine, 
an ASMase inhibitor, suppressed apoptotic responses induced by -T3 treatment. 
Silencing ASMase using siRNA reduced the cleavage of caspase 8 and PARP by -T3, 
which support the role of ASMase in -T3 induced apoptotic response. Interestingly, 
AMSase knockdown also suppressed the activation of JNK and the upregulation of 
GRP78, CHOP and DR5 expression (Figure 3.9.B), suggesting ASMase plays a role in 












Figure 3.9. Inhibition of ASMase partially suppressed -T3-induced ER 
stress and apoptosis.  A, MDA-MB-231 cells at 2.5X10
6
/plate were seeded in 
100 mm plates. Cells were pre-treated with DMSO or 10 µM of desipramine for 
2 hrs followed by treatments with 30 M of -T3 or ethanol (0.08%) for 18 hrs. 
Cells were collected and analyzed for the annexin V/PI labeling (Des: 
despipratmine). B, MDA-MB-231 cells at 2.0X10
6
/plate were seeded in 100 mm 
plates. Cells were transfected with control or ASMase siRNA for 48 hrs. Then 
cells were treated with 30 M of -T3 for 18 hrs. Cells were collected and 









































Several studies addressing the ability of natural tocotrienols to mediate anti-carcinogenic 
and anti-angiogenic effects in animal models or in cells in culture have been reported 
(reviewed by (4)); however, the mechanisms involved in the anticancer effects of 
tocotrienols are not clearly understood especially in animal models. Among the reported 
mechanisms of action, apoptosis induction is considered to play a major role in the anti-
proliferative effects of tocotrienols (107). This study was focused on understanding the 
molecular mechanisms of in vivo anticancer activity of -T3 in relation to its proapoptotic 
activities in cell culture studies. Previously, we found that -T3 attenuates mouse 
mammary tumor growth in a syngeneic animal model (described in Chapter 2). Here, 
based on the immunohistochemical analyses of tumor sections, we found that -T3 
suppressed tumor growth by inhibiting cell proliferation and also by inducing apoptosis 
in vivo. In order to follow up on the anticancer mechanisms observed in vivo, tocotrienol 
effects on in vitro colony formation was analyzed. While the inhibitory effect of -T3 on 
cancer cell division correlated with the anti-tumor effects observed in the animal study, 
the inhibitory effect of -T3 on colony formation did not match data generated in the 
animal study. These results suggest that anticancer efficacy of -T3 is less effective than 
-T3 as previously suggested by Yu et al. based on the apoptogenic activity of each form 
of tocotrienols in human breast cancer cell lines (91) and by Constantinou et al. as 
reported for human prostate cancer cell lines (87) in cell culture. A previous study by 
MacAnally et al. demonstrated that dietary delivery of -T3 at a dose of 250 mg/kg diet 
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reduced 50% of mean weight of melanomas compared to the control group in a syngeneic 
mouse model (33). In our previous study, -T3 at a dose of 250 mg/kg diet reduced 
mammary tumor burden by 35%. Although we did not test -T3 in vivo, it is possible that 
-T3 might exhibit a better efficacy than -T3 in vivo, since the inhibitory effect of -T3 
on colony formation and its apoptogenic ability was the highest among -, - or -T3 in 
all cell lines tested (Table 3.1 & Figure. 3.2). Constantinou et al. reported that -T3 was 
the most potent of all eight natural forms of vitamin E when tested on human prostate 
cancer cells in cell culture (87).  
Data reported in previous studies showed that tocotrienols induce cell cycle arrest and 
apoptosis in colon and prostate cancer cells (21, 26); whereas, data reported in our study 
suggest that anti-proliferative effects of tocotrienols are mostly derived from apoptogenic 
actions; however, the possibility of the induction of cell cycle arrest by -T3 was not 
excluded. Mechanisms involved in apoptosis induced by tocotrienols in breast cancer 
cells have been studied using mouse +SA neoplastic mammary epithelial cells, in which 
caspase-8 and caspase-3 activations are required for -T3-induced apoptosis but no 
involvement of Fas signaling was detected (28, 108). In our study, we hypothesized that 
death receptor signaling would be involved in -T3 induced apoptosis based on the 
activation of caspase-8 and the upregulation of DR5 in the human breast cancer cells. 
Silencing DR5 using siRNA partially blocked -T3 triggered apoptosis indicating 
involvement of death receptor signaling. Upregulation of DR5 was observed following -
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T3 treatment in all cells regardless of p53 status: MCF-7 cells have wild type p53, MDA-
MB-231, MDA-MB-468 and T47D cells have p53 missense mutations (109). Here, we 
showed that DR5 expression is regulated, at least in part, by CHOP, a downstream 
effector protein of ER stress. CHOP-dependent activation of DR5 expression has been 
recently reported in different types of cancer cells treated with drugs, including 
lonafarnib (a farnesyltransferase inhibitor), a novel synthetic triterpenoid (methyl-2-
cyano-3,12-dioxooleanan-1,9-dien-28-oate; CDDO-Me), and 2,4-dimethyl-celecoxib (a 
cyclo-oxygenase-2 inhibitor) (95, 108, 110). We showed that silencing CHOP reduced 
the increase in DR5 protein expression and decreased apoptotic responses following -T3 
treatment. Using a chromatin immunoprecipitation assay, we further showed that CHOP 
directly binds to the DR5 promoter following -T3 treatment. This is the first report 
showing -T3 induces apoptosis via the upregulation of DR5 which is directly activated 
by CHOP. Furthermore, our study supports the finding of a previous gene expression 
study that reported increased CHOP transcript levels in tocotrienol-rich fraction (TRF) 
treated MDA-MB-231 and MCF-7 cells (32).  
Observation of CHOP upregulation led us to further investigate the involvement of ER 
stress in -T3 induced apoptosis. We observed upregulation of ER chaperon GRP78 both 
in mRNA and protein, nuclear localization of ATF4 and the splicing of XBP-1 mRNA 
from 4 to 8 hrs after -T3 treatments. Signal transduction events associated with ER stress 
are thought to be mediated by three ER transmembrane proteins: Ire 1, PKR-like ER 
kinase (PERK), and activating transcription factor 6 (ATF6) (58). The N termini of these 
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transducers are normally bound by ER chaperone GRP78, preventing their aggregation 
(52). When unfolded proteins accumulated in the ER, GRP78 binds unfolded proteins and 
the ER membrane proteins become dissociated from GRP78 resulting in their activation. 
Activation of PERK which is a Ser/Thr protein kinase results in the phosphorylation and 
inactivation of the eukaryotic initiation factor 2 (eIF2) followed by translational 
induction of ATF4 (58). Activated ATF6, a basic leucine zipper (bZIP) containing 
transcription factor, induces genes with ER stress response elements (ERSE) in their 
promoter. GRP78 and XBP-1 are among the identified target genes of ATF6 (111). The 
other ER stress transducer, Ire-1 contains both Ser/Thr kinase domains and an 
endonuclease domain. Upon activation, its endonuclease activity processes XBP-1 
mRNA to generate spliced forms of XBP-1 which encode a stable, active transcription 
factor (105). CHOP has been reported to be transcriptionally regulated by ATF4; as well 
as, XBP-1 (52), therefore our study suggests that ER stress induced by tocotrienol 
treatment contributes to increased expression of CHOP which plays a key role in DR5-
mediated apoptosis. A recent study using mouse +SA mammary epithelial cells treated 
with -T3 showed induction of ER stress; however, unlike our study neither caspase 8 
activation nor death receptor signaling was involved (112). This does not appear to be a 
species difference since the highly metastatic 66cl-4-GFP mouse mammary tumor cell 
line that we used in our in vivo study exhibits increased DR5 expression after -T3 
treatment (data not shown). 
87 
 
We showed a time-dependent phosphorylation of JNK and p38 MAPK after -T3 
treatment. While a marked activation of JNK was observed to occur in a time and dose-
dependent manner, the activation of p38 MAPK occurred gradually 12 to 16 hrs after -
T3 treatment. To ascertain their role in the apoptotic response, siRNA was used. 
Knockdown of either JNK or p38 MAPK partially blocked -T3-mediated apoptosis, and 
also reduced the upregulation of CHOP and DR5. Since CHOP is a downstream marker 
of ER stress, we tested if the phosphorylation of JNK and p38 MAPK was influenced by 
ER stress. Salubrinal is known to selectively protect cells from ER stress induced 
apoptosis by inhibiting the dephosphorylation of eIF2 which is phosphorylated by 
PERK (106). Salubrinal was capable of partially protecting the cells from -T3-induced 
apoptosis and it also partially blocked the activation of JNK and p38 MAPK. These 
results suggest that the activation of JNK and p38 MAPK is partially connected to ER 
stress mediated events. There are several reports showing that activation of JNK and/or 
p38 MAPK in response to ER stress is critical for inducing apoptosis (95, 96, 110). Ire-1, 
one of three ER stress transducers, has been shown to activate apoptosis signal-regulating 
kinase 1 (ASK1) which causes JNK and p38 MAPK activation (53). However, it is 
unclear how dephosphorylation of eIF2 by salubrinal suppressed the phosphorylation of 
JNK or p38 MAPK as we observed in our study. It appears that the role of JNK and p38 
MAPK activation in ER stress-induced apoptosis varies in different cell types; as well as 
varies based on the nature of the ER stress inducer.  
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Finally, upregulation of Grp78, CHOP and DR5 and increased PARP cleavage were 
observed in cells treated with either -T3 or TRF suggesting that other forms of 
tocotrienols may trigger apoptosis coupled with ER stress which eventually activates 
DR5 expression in a CHOP-dependent manner. In order to understand the detailed 
mechanisms of how tocotrienols induce ER stress, ASMase involvement was assessed.  
In mouse and human T-cells, ceramide induces apoptosis mediated by ER stress in a p38 
MAPK and JNK dependent fashion (110). Previous studies in our lab showed that -
tocopherol ether-linked acetic acid (-TEA), a derivative of R,R,R--tocopherol, 
activates ceramide accumulation in the cell membrane, and inhibition of ceramide 
accumulation by a chemical inhibitor or siRNA inhibited -TEA induced apoptosis (113). 
Therefore, it was of interest to see if modulation of the ceramide signaling pathway by 
tocotrienols initiates ER stress. Data presented here show that ASMase inhibition with 
either a chemical inhibitor or siRNA suppressed ER stress, caspase 8 cleavage and 
apoptosis induced by -T3. Further studies are needed to figure out the exact role of 
ASMase activity in -T3-induced apoptosis.  
In conclusion, the present study showed that -T3 when fed in the diet suppressed 
mammary tumor growth in vivo which was correlated with decreased cell proliferation 
and increased apoptosis. In vitro data demonstrated that apoptosis triggered by 
tocotrienols is mediated, at least in part, by ER stress induced by ASMase action. ER 
stress activation of JNK and p38 MAPK followed by upregulation of DR5 in a CHOP 
dependent manner in human breast cancer cells in cell culture was demonstrated to be 
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involved in -T3-induced apoptosis (summarized in Figure. 3.10). Studies suggest that 




Figure 3.10.  Proposed model for -T3 induced apoptosis mediated by ER 
stress. Diagram of signal transduction mediators identified and investigated in 
these studies. The causal nature of these mediators was established by siRNA 

















Chapter 4. Investigation of -tocopherol as an anticancer agent in breast cancer cells 
and animal models.  
R,R,R--Tocopherol (-T), the major vitamin E compound consumed from food sources 
in the US, has been shown to have a positive correlation with lowering cancer risk in 
humans; however its anticancer mechanism of action is not well understood. Data 
presented here show that -tocopherol induces apoptosis and also sensitizes Tumor 
necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) resistant human breast 
cancer cells to undergo apoptosis by enhancing death receptor (DR5) expression not only 
at mRNA and protein levels but also by increasing cell surface expression. Cell surface 
increase of DR5 by -T triggered caspase-8 cleavage followed by increases in 
mitochondrial permeability, cytochrome c release and caspase-9 cleavage. In agreement 
with in vitro studies, dietary delivery of -T significantly suppressed the tumor growth 
rate of MDA-MB-231 human breast cancer cells in a xenograft model. In an effort to 
improve anti-tumorigenic potency of -T, we tested sesamin, a natural source human 
cytochrome P450 (CYP) inhibitor extracted from sesame seeds, for improving in vivo 
tissue bioavailability of -T. Data support that dietary supplementation with sesamin and 
-T increase liver and tumor retention of -T compared to single supplementation with -
T. These data suggest that -T can be used singly or in combination with sesamin as a 





Due to early detection followed by adjuvant therapy, breast cancer incident and mortality 
during past decades have decreased; however breast cancer still ranks as the second 
leading cause of cancer death in the US and remains the most commonly diagnosed 
cancer in US women (114, 115).  While novel chemotherapeutics as well as early stage 
diagnosis and screening methods have improved breast cancer outcomes, risk-reduction 
and preventive strategies remain a challenge (116). Hormone-based prevention using 
selective estrogen receptor modulators or aromatase inhibitors have proven effective in 
estrogen-driven breast cancer and observational studies on lifestyle factors such as 
dietary fat, body weight, alcohol intake or intake of several micronutrients suggest 
additional targets for reducing breast cancer (115). Limited evidence is available 
regarding correlations between overall breast cancer risk and nutrient factors including 
dietary fat, carbohydrate, fruits and vegetable or micronutrients; therefore, association of 
breast cancer risk with individual nutrient factors requires more studies (114).  
R,R,R--Tocopherol (-T), is a vitamin E compound that shares a structural similarity and 
lipid-soluble antioxidant property with R,R,R--tocopherol (-T), the predominant form 
of vitamin E in plasma and tissue. -T is the most tested vitamin E form both in clinical 
trials and preclinical studies; however, positive correlations of -T, synthetic -T (all-
racemic--tocopherol) or their acetate derivatives with reduction of human cancer risk 
has not been observed (3). Instead, studies using -T, the most highly consumed form of 
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vitamin E in the US, suggests the possibility of using -T as an effective chemopreventive 
agent in various cancers. Several clinical trials or observation studies about -T have been 
conducted. Among these, the CLUE studies best exemplify the potential chemo-
preventive effect of -T in human prostate cancer (12, 13). In these studies, higher serum 
-T levels were associated with reduced risk of developing prostate cancer (13). In 
addition, previous epidemiologic studies showed that serum concentration of -T, but not 
of -T, was relatively lower in patients with upper aerodigestive tract cancer or prostate 
cancer than the control subjects (117, 118). Cell culture studies using various human 
cancer cells have identified possible mechanisms of anticancer actions of -T. In human 
colon cancer cells, -T reduced DNA synthesis; decreased cyclin D1 and E expression 
levels; increased peroxisome proliferator activator receptor- (PPAR-) protein 
expression; and also induced apoptosis in a caspase-8 dependent manner (15, 119, 120). 
In human prostate cancer cells, reduction of cyclin D1, cell growth inhibition and the 
induction of apoptosis linked with interrupting de novo sphingolipid synthesis pathways 
were observed after -T treatment (14, 121). Although aforementioned clinical and 
preclinical studies strongly support possible cancer preventive or anti-proliferative effects 
of -T in prostate cancers and colorectal cancers, its application in other types of cancers 
remains to be investigated.  
Elimination of ingested vitamin E compounds in the liver involves -hydroxylation of 
the phytyl side chain by cytochrome P450 enzymes (CYP)-dependent processes followed 
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by several steps of -oxidation (8). In the liver, tocopherol transfer protein (TTP) 
discriminates between different forms of vitamin E for enrichment of -T into nascent 
very low density lipoproteins (VLDL) which are subsequently transformed into low-
density lipoproteins (LDL), the major carrier for -T in blood (8). CYP3A4 and CYP4F2 
are known to be the major P450 enzymes that are involved in vitamin E metabolism (8), 
and -T have been shown to activate pregnane X-receptor, a nuclear receptor that 
induces gene expression of drug metabolizing enzymes such as CYP3A4 (10). Studies 
support that tissue concentrations of -T are limited due to CYP3A-mediated hepatic 
catabolism of -T in the liver, which may hinder the use of -T as a chemopreventive or 
an anti-cancer agent.  
Data presented here demonstrated that -T displays anticancer effects both in cell culture 
studies and in a xenograft mouse tumor model. -T induced apoptosis in MDA-MB-435 
and MCF-7 human breast cancer cells in a dose- and time-dependent manner in cell 
culture via activating death receptor 5 (DR5) signaling. Pre- or co-treatment of TRAIL-
resistant human breast cancer cells with -T and TRAIL induced apoptosis. Dietary 
delivery of -T significantly attenuated tumor growth in a xenograft mouse model 
transplanted with MDA-MB-231-GFP human breast cancer cells. Improvement of -T 
bioavailability in tissues was observed after co-treatment of -T with sesamin, a natural 




4.2. Materials and Methods.  
4.2.1. Cell culture and reagents 
The maintenance and culture conditions for MDA-MB-435, MDA-MB-231 and MCF-7 
human breast cancer cells were previously described (18, 99). All human breast cancer 
cells were obtained from the American Type Culture Collection (ATCC). Human 
mammary epithelial cells (HMEC; Cooperative Human Tissue Network, Birmingham, 
AL) were primary cultures of human mammary cells derived from normal mammoplasty 
specimens as described previously (80). For the treatment, FBS was reduced to 2% to 
better mimic low in vivo serum exposure of these cell types. -T and -T were purchased 
from TAMA biochemical company (Tokyo, Japan) and dissolved in DMSO at 200 mM 
and further diluted with ethanol to 40 mM. Equivalent amount of DMSO:ethanol (1:4) 
were used as vehicle control. Sesamin was purchased from Cactus Botanics Ltd. (London, 
England). TRAIL was purchased from Alexis Biochemicals (San Diego, CA).  
4.2.2. Quantification of apoptosis (Annexin V assay) 
Percentage of apoptotic cells after treatment was evaluated using Annexin V- Fluorescein 
isothiocyanate (FITC)/Propidium iodide (PI) assay or Annexin V-Phycoerythrin (PE) 
assay as previously described (17). Briefly, cells were collected at indicated time points 
and resuspended in Annexin V binding buffer (10 mM HEPES (pH 7.4), 150 mM NaCl, 
5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2). Cells were incubated with Annexin V-FITC 
(Invitrogen, CA) for 8 min at room temperature, and then suspended in PI solution (50 
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ng/mL in PBS). Fluorescence was measured using flow cytometry (FACSCalibur, BD 
Biosciences, San Jose, CA) and data were analyzed using CellQuest software 
(FACSCalibur, BD Biosciences). The half maximal effective concentration inducing 
apoptosis in 50% of the cell population (EC50) was determined using Graphpad Prism 
software.  
4.2.3. Western blot analyses 
Whole cell lysates were used to analyze protein expression levels as previously described 
(99). Primary antibodies used in this study were as follows: PARP (Santa Cruz 
Biotechnology, Santa Cruz, CA); Bid and Bax (BD Pharmingen, Rockville, MD); 
caspase-8 and caspase-9 (Cell Signaling Technology, Beverly, MA); DR5 (Cell Sciences, 
Canton, MA). The antibody to GAPDH was produced in house. Secondary antibodies 
conjugated with horseradish peroxidase included goat anti-rabbit and rabbit anti mouse 
IgG (Jackson Immunoresearch, Rockford, IL); and bovine anti-goat IgG (Santa Cruz 
Biotechnology). To quantitate the expression level, densitometric analyses were 
conducted using Scion Image Software (Scion Corporation, Frederick, MD) after 
normalization to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) which was used 
as a loading control.  
4.2.4. FACS analyses of cell surface expression of DR4 and DR5 and their ligand 
TRAIL 
Cell surface expression of DR4, DR5 and TRAIL was determined using FACS analyses. 
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Treated or control cells were detached and washed three times with 0.5% BSA in PBS. 
Cells (25 μl of 8 × 106 cells/ml in 0.5% BSA in PBS) were incubated with 1 μg normal 
mouse IgG1 or IgG2b for 15 min at room temperature followed by incubation with 
phycoerythrin-conjugated antibodies to DR4, DR5 or TRAIL or phycoerythrin-
conjugated isotype immunoglobulins (R&D Systems, Minneapolis, MN) for 45 min. 
Intensity of red fluorescence was detected using a FACSCalibur flow cytometer and data 
were analyzed using CellQuest software. 
4.2.5. Detection of active (conformationally changed) Bax 
Active (conformationally changed) Bax was detected as described previously (99). 
Briefly, 500 μg protein from whole cell extracts/0.5 ml was incubated overnight at 4°C 
with 2 μg of anti-Bax 6A7 (Sigma-Aldrich, St. Louis, MO), an antibody that specifically 
recognizes conformationally changed Bax, followed by reaction with 20 μl of protein G-
agarose beads (Calbiochem, San Diego, CA) for 2 hours at 4°C. Protein was analyzed by 
SDS-PAGE followed by immunoblotting with regular anti-Bax antibody. 
4.2.6. Detection of mitochondrial permeability transition 
The effect of γ-T on mitochondrial membrane potential was measured using the dye JC-1 
(5,5′,6,6′-tetrachloro-1,1′,3,3′ tetraethylbenzimidazolylcarbocyanine iodide/chloride; 
Molecular Probes, Carlsbad, CA ). The JC-1 dye bearing a positive charge enters intact 
mitochondrial membrane due to the negative charge established by the intact 
mitochondrial membrane potential, accumulates as aggregates producing a red 
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fluorescence (122). In the absence of intact mitochondrial membrane, JC-1 accumulates 
in the cytoplasm as a monomeric form characterized by green fluorescence (122). Cells 
were collected after indicated treatment of -T or vehicle, incubated with JC-1 for 30 min 
at 37°C followed by PBS wash. Red and green fluorescence intensity was measured 
using a FACSCalibur flow cytometer and data were analyzed using CellQuest software. 
4.2.7. Detection of cytochrome c release from mitochondria into cytosol 
A rapid and reliable technique to detect cytochrome c release during drug-induced 
apoptosis by FACS analyses was used (123). To detect cytochrome c release after -T 
treatment, cells were treated, collected and incubated with 100 μl digitonin (50 μg/ml in 
PBS with 100 μM KCl) for 5 min on ice followed by fixing the cells with 4% 
paraformaldehyde in PBS for 20 min at room temperature, and incubating the cells in 
blocking buffer (3% BSA and 0.05% saponin in PBS) for 1 h. Cells were incubated with 
anti-cytochrome c antibody (clone 6H2.B4, BD Pharmingen, San Diego, CA) at 1:200 in 
blocking buffer overnight at 4°C, washed three times with PBS, and then incubated with 
FITC-labeled secondary antibody in blocking buffer for 1 h at room temperature. 
Cytochrome c fluorescence intensity was determined using a FACSCalibur flow 
cytometer and data were analyzed using CellQuest software. 
4.2.8. Semi-quantitative reverse transcription PCR analysis 
Semi-quantitative analyses were conducted (following company instructions) to detect 
DR5 mRNA expression by reverse transcriptase-polymerase chain reaction (RT-PCR) 
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with Superscript RTase (250 U, Invitrogen) and Duplex PCR with Taq PCR Master Mix 
Kit (Qiagen Inc), respectively as described by Martin et al. (124). Primers for DR5 (478 
bp) were: forward 5‟-GCCTCATGGACAATGAGATAAAGGTGGCT-3‟ and reverse 
5‟-CCAAATCTCAAAGTACGCACAAACGG-3‟, and for β-actin (202 bp) were: 
forward 5‟-GGCGGCACCACCATGTACCCT-3‟ and reverse 5‟-AGGGGCCGGACTC-
GTCATACT-3‟. PCR conditions employed were: 94°C for 3 min for initial denaturation, 
35 cycles at 94°C for 1 min for denaturation, 61°C for 1 min for annealing and 72°C for 2 
min for elongation. PCR fragments were separated by electrophoresis on a 1.5% agarose 
gel and visualized by staining with ethidium bromide. 
4.2.9. Transfection with DR5 and FADD siRNA 
Cells were transiently transfected with siRNAs against DR5 or FADD (Ambion, Austin, 
TX) using a reverse transfection protocol following manufacturer‟s instructions. A 
negative control siRNA (Ambion, Austin, TX), which has no significant sequence 
similarity to any mouse, rat or human gene sequences, was used to control for any 
nonspecific effects on gene expression. Optimal conditions were determined using 
Silencer CellReady siRNA Transfection Optimization and GAPDH Kit provided by 
Ambion. Briefly, for each well of a 6 well plate, 9 μl transfection agent; siPORT NeoFX 
(Ambion, Austin, TX) was mixed with 0.5 ml serum free media (OPTI MEM-I) and 
incubated at room temperature for 10 min followed by addition of 2.3 μl siRNA (20 μM). 
The mixture of transfection agent and siRNA was incubated at room temperature for 10 
min followed by mixing with 1 ml cells at 3.75 × 10
5
/ml in culture media. Cells were 
99 
 
cultured for 1 day followed by replacement of the transfection media with culture media 
and incubating for an additional day. Transfected cells were split in 100 mm dish at 3 × 
10
5
 cells for 8 hrs prior to γ-T treatments for 2 days. 
4.2.10. Animal study   
All animal experiments were conducted according to „Guidelines for the Humane 
Treatment of Animals‟ as designated by the University of Texas Institutional Animal 
Care and Use Committee. Immune compromised Nu/Nu female BALB/c mice at 6 weeks 
of age (approximately 20 g in weight) were purchased from Jackson Laboratories (Bar 
Harbor, ME).  
For tumor growth rate analyses, MDA-MB-231-GFP human breast cancer cells (gift from 
Dr. LuZhe Sun, Department of Structural Biology, University of Texas Health Science 
Center at San Antonio, San Antonio, TX) in 100 l of 50% matrigel (BD Biosciences, 
Franklin Lakes, NJ) were injected into the inguinal area at a point equal distant from the 
fourth and fifth nipples on the right side. About 1 wk after tumor cell injection, the mice 
were randomly assigned to 4 groups (10 mice/group): control, -T, -T and -T+-T 
when the tumors reached an average volume of 25 mm
3
 and fed with semi-purified and 
tocopherol-stripped AIN-76A diets purchased from Harlan Teklad (Madison, MI). 
Control diet contained tocopherol-stripped purified AIN-76A diet containing 33 IU all-
rac--tocopherol acetate per kg diet to meet the estimated vitamin E nutrient requirement 
for mice (83). To this basal (control) diet, different forms of vitamin E were added at 500 
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mg/kg each: thus, the combination diet contains (500 mg of -T + 500 mg of -T)/kg diet. 
HPLC analyses of the actual concentrations of supplemented vitamin E forms in the diet 
following -irradiation to permit food entry into the barrier facility housing the nude mice 
were as follows: -T: 378 mg/kg diet; -T: 358 mg/kg diet; (456 mg of -T + 506 mg of 
-T)/kg diet. The average food intake was 3.70.1 g/day/mouse. With this amount of food 
intake, 500 mg of -T/kg diet provided approximately 400 IU vitamin E, an amount 
typically found in one vitamin E soft gel capsule to an individual mouse on a daily basis 
based on body surface equivalency of a mouse to human (84).  Tumors were measured 
using calipers every other day, and tumor volumes were calculated using the formula: 
volume (mm
3
) = (width x width x length/2). Body weights were determined weekly. 
Animals were euthanized after 24 days of dietary treatment. 
To assess the impact of sesamin on -T tissue availability, immune compromised Nu/Nu 
female BALB/c mice at 4-6 weeks of age were purchased from Jackson Laboratories 
(Bar Harbor, ME). A 0.72 mg -estradiol 60 days release pellet (which is comparable to 
levels of estrogen in women in mid-cycle) was implanted subcutaneously between the 
shoulder blades of each mouse using a Trocar. After 4 days, 2X10
6
 MCF-GFP 
cells/mouse in 100 ml of 50% matrigel (BD Biosciences, Franklin Lakes, NJ) were 
injected into the inguinal area at a point equal distant from the fourth and fifth nipples on 
the right side. When the tumors were palpable, mice were randomly assigned to four 
groups (n=5): control, sesamin, -T and sesamin+-T groups and fed with semi-purified, 
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tocopherol-stripped AIN-76A diets purchased from Harlan Teklad (Madison, WI). 
Control diet consisted of the tocopherol-stripped purified AIN-76A diet supplemented 
with 60 IU all-rac--tocopherol acetate per kg diet to meet the estimated vitamin E 
nutrient requirement for mice (83). To this basal (control) diet, sesamin was added at 1.3 
g/kg sesamin diet, -T was added at 250 mg/kg -T diet, and sesamin + -T was added at 
(1.3 g sesamin+250 mg -T) /kg sesamin + -T diet. Tumor bearing mice were fed the 
respective diets for 40 days. Tissues and sera were collected when animals were 
sacrificed.  
4.2.11. Tumor immunohistochemistry  
Primary tumors from 5 individual mice in each group were collected at the time of animal 
sacrifice and fixed in 10% formalin. Samples were processed for immunohistochemical 
analyses by the Histological & Tissue Processing Facility Core 3 at the University of 
Texas M.D. Anderson Cancer Center-Science Park Research Division (Smithville, TX) 
as previously describe (41, 79). Briefly, deparaffinized tumor sections (5 m) were 
examined using antibody against Ki-67, a biomarker for determining active cell division 
and  terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay 
for determining number of apoptotic cells. For Ki-67 analyses, 5 randomly chosen 
microscopic fields (X400) per tumor were scored. For TUNEL analyses, at least 15 




4.2.12. HPLC detection of vitamin E compounds in serum  
Sera and tissues were snap frozen in liquid nitrogen at the time of animal sacrifice and 
kept in -80C until analyzed. Lipids were extracted from each sample and different forms 
of tocopherols or sesamin were measured by an internal standard method using reverse-
phase HPLC (high performance liquid chromatography) with fluorometric detection as 
described by Tirmenstein et al. (125). Each sample was dissolved in methanol and 40 l 
of each sample was injected into a Waters 717 HPLC equipped with an autosampler. The 
mobile phase consisted of 96% methanol (HPLC grade; Aldrich, Milwaukee, WI), 4% 
water, and 0.001% glacial acetic acid. Samples were separated on a Waters spherisorb 
ODS-2 5u (250 x 4.6-mm) column (Alltech, Deerfield, IL). Excitation and emission 
wavelengths of 290 and 330 nm, respectively, were used for all determinations. 
Quantification of the separated compounds was performed based on the internal standard 
method using -tocotrienol as the internal standard and Millennium-32 chromatography 
manager software for data analyses (Waters Corp., Milford, MA).  
4.2.13. Statistical analyses 
Tumor growth was evaluated by transforming volumes using a logarithmic transform 
(base 10) and analyzed using a nested two-factor analysis of variance (ANOVA) with 
SPSS (SPSS Inc, Chicago, IL). Differences in tumor growth rate, number of TUNEL 
positive cells and Ki-67 positive cells, and serum levels of -T and -T were determined 
using the ANOVA/Turkey‟s multiple comparison test and Mann-Whitney rank test with 
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Prism software version 4.0 (Graphpad, San Diago, CA). Tissue levels of -T and sesamin 
were compared using the student t-test (two-tailed, unpaired). Apoptotic data were 
analyzed using a one-way analyses of variance (ANOVA) followed by Tukey post hoc 




4.3.1. -T, but not -T induced apoptosis in human breast cancer cells 
The ability of tocopherols to induce apoptosis in MDA-MB-435 and MCF-7 human 
breast cancer cells in cell culture was evaluated using DAPI staining for visualizing DNA 
fragmentation,  western blot assay for PARP cleavage, or Annexin V/PI assay. First, the 
number of cells with condensed/fragmented nuclei were observed with DAPI staining 
and counted following treatment with 10, 20 or 40 μM of -T or γ-T for 3 days. As 
shown in Figure 4.1.A, γ-T showed a dose-dependent increase in percentage of apoptotic 
cells in MDA-MB-435 and MCF-7 cells but not in normal human mammary epithelial 
cells (HMEC); whereas -T, the most abundant vitamin E form in human plasma and 
tissues, at equivalent concentrations (namely, 10-40 μM) did not induce apoptosis in any 
of the three cell types (Figure 4.1.A). PARP cleavage into 89 kDa fragments was 
observed in a dose dependent manner after γ-T treatment in both cell types (Figure 4.1.B) 
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and 40 M of γ-T treatments for 2 and 3 days increased the number of annexin V positive 
cells in both cell lines (Figure 4.1.C), all of which confirm apoptogenic ability of γ-T in 




Figure 4.1. γ-T induced apoptosis in human breast cancer cells but not in 
HMECs. A & B, Cells were treated with 10, 20 or 40 μM of -T or γ-T for 3 
days, stained with DAPI, and percentage of apoptotic cells was determined by 
DAPI assay or western immunoblot analyses of PARP cleavage, respectively (a: 
significantly different from vehicle control; b: significantly different from vehicle 
control and 10 M treatments; and c: significantly different from all treatments, 
p< 0.05). C,  Cells were treated with 40 μM of γ-T for 2 and 3 days and apoptotic 
cell population was analyzed by FACS analyses of Annexin V positive cell. (*: 
significantly different from the vehicle control (p< 0.05). Data in A and C are 
represented as mean ± SD of three independent experiments. Data are adopted 
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4.3.2. -T sensitized human breast cancer cells to TRAIL induced apoptosis 
Previously, HMEC and several breast cancer cell lines including MCF-7 were reported to 
be resistant to TRAIL induce apoptosis (126). In a preliminary study, MDA-MB-435 also 
showed resistance to TRAIL induced apoptosis as much as MCF-7 in comparison to 
TRAIL sensitive MDA-MB-231 cells (data not shown). Pre-treatment of MDA-MB-435 
cells with γ-T (40 μM) for 1 day followed by treatment with 10 ng/ml of TRAIL for 2 
days significantly sensitized cells to respond to TRAIL-induced apoptosis, whereas 
treatment of cells with 10 ng/ml of TRAIL alone did not induce apoptosis (Figure 4.2.A). 
Employing the same treatments to HMECs did not induce any apoptosis (Figure 4.2.A) 
suggesting γ-T selectively sensitized cancer cells, but not normal cells to TRAIL-induced 
apoptosis. This difference is likely due to the cancer cell-selective properties of TRAIL as 
documented previously (126).  Similarly, co-treatment of γ-T at sub-apoptotic dose (20 
μM) with 10 ng/ml of TRAIL for 2 days also enhanced the sensitivity of the breast cancer 






Figure 4.2. γ-T sensitized MDA-MB-435 cells to TRAIL-induced apoptosis. 
A, Cells were pre-treated with 40 μM of γ-T for 1 day and the treatment medium 
was removed followed by treatment with 10 ng/mL of TRAIL for 2 days. Cells 
were collected and the percentage of apoptotic cells was determined by DAPI 
assay (a: significantly different from vehicle control; and b: significantly 
different from vehicle control, γ-T alone, and TRAIL alone). B, For pre-
treatment with -T (pre--T), cells were pre-treated with 40 μM of γ-T for 1 day 
and the treatment medium was removed followed by treatment with 10 ng/mL of 
TRAIL for 2 days. For -T, cells were co-treated with 20 M of -T + 10 ng/mL 
of TRAIL for 2 days. Data in A and B are represented as mean ± SD of three 













4.3.3. -T induced increases of DR5 mRNA, protein and cell surface expression level 
To figure out how -T reverses TRAIL-resistance in human breast cancer cells, the cell 
surface expression level of DR4 and DR5 and their ligand TRAIL were analyzed using 
specific antibodies labeled with fluorescence. As shown in Figure 4.3.A, membrane 
bound TRAIL or DR4 expression levels were not changed after -T treatment. On the 
other hand, DR5 expression was greatly increased in both MCF-7 and MDA-MB-231 
cells. Further analyses using RT-PCR and western blot assays showed that expression of 
both mRNA and protein levels of DR5 were induced after -T treatment (Figure 4.3.B). 
These data suggest that DR5 expression is regulated at the transcriptional level by -T 
treatment, and translated DR5 is localized on the cell surface.  
4.3.4. Silencing DR5 or Fas-associated death domain (FADD) partially 
blocked -T induced apoptosis 
TRAIL binding to death receptors can initiate the subsequent recruitment of adaptor 
protein FADD and caspase-8 via an interaction between their death domains (DD) to 
form a death inducing signaling complex (DISC). To understand the role of DR5 in the 
apoptotic process triggered by -T, siRNA against either DR5 or FADD were transfected 
to MDA-MB-435 cells prior to -T treatment. Knockdown of DR5 or FADD significantly 
blocked -T-induced apoptosis in MDA-MB-435 cells (Figure 4.4.A & B). Knockdown 
of DR5 also restored TRAIL resistance and rendered the cells non-responsive to -T pre-
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treatment plus TRAIL treatment (Figure 4.4.C), indicating a critical role for DR5 in -T‟s 




Figure 4.3. γ-T induced increases of DR5 mRNA, protein and cell surface 
membrane expression. A, Cells were treated with 40 μM of γ-T for 2 days and 
the membrane expression levels of TRAIL, DR4 and DR5 were analyzed by 
fluorescent antibody labeling followed by FACS analyses. B, Cells were treated 
at indicated time points and analyzed for DR5 mRNA level by RT-PCR (upper 
two panels) and protein level by western blot (lower two panels). Internal 
controls, -actin for RT-PCR and GAPDH for western blot were used. All data 
are representative of two or more independent experiments. Data are adopted 
from Yu et al. (16). 
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Figure 4.4. Silencing DR5 or FADD suppressed γ-T induced apoptosis. A & 
B, MDA-MB-435 cells were transiently transfected with siRNA targeting DR5 or 
FADD followed by treatment with 40 μM of γ-T for 2 days. Non-specific siRNA 
was used as a negative control (Ctrl). Apoptotic cells were identified using the 
annexin V/PI assay (A). Data are depicted as meanSD of three independent 
experiments. Apoptotic response was also confirmed by checking PARP 
cleavage (arrow points to cleavage fragment). Knockdown of DR5 and FADD 
was confirmed by western blot analyses (B). C, MDA-MB-435 cells were 
transiently transfected with siRNA targeting DR5. Non-specific siRNA was used 
as a negative control (Ctrl). Transfected cells were pre-treated with γ-T (40 M) 
for 1 day followed by exchange of new cell culture medium with 10 ng/ml of 
TRAIL for 1 day. Percentage of apoptotic cells was analyzed using the annexin 
V/PI assay. Data are depicted as meanSD of two independent experiments. 
*Significant difference in comparison to Ctrl (P<0.05). Data are adopted from 



































4.3.5. -T induced-apoptosis involved changes in mitochondrial integrity.    
Since we observed DR5 and FADD involvement in -T induced apoptosis, we 
investigated downstream apoptotic signaling events. First of all, cleavage (activation) of 
two initiation caspases: namely, caspase-8 and -9 were analyzed using western blot. Not 
surprisingly, cleavages of both caspase 8 and 9 were observed after -T treatment in a 
time dependent manner (Figure 4.5.A, upper two panels). Truncation of Bid (tBid), a 
member of the BH3 only proapoptotic Bcl-2 family proteins as well as activation of Bax 
were observed upon -T treatment (Figure 4.5.B, lower two panels), suggesting that 
caspase-8 processed Bid to tBid which further activated Bax activation following  
treatment with -T. These proapoptotic Bcl-2 family proteins are well-documented for 
their impact on mitochondrial integrity. In this regard, we further analyzed mitochondrial 
potential using JC-1 which exhibits a mitochondrial potential-dependent fluorescence 
shift: the higher the ratio of green to red, the lower mitochondrial potential. As shown in 
Figure 4.5.B, cells with green signal were increased upon -T treatment, indicating cells 
lost mitochondrial potential after -T treatment. Cytochrome c release was also assessed 
using indirect immunofluorescence staining followed by FACS analysis (Figure 4.5.C). 
Consistently, cytochrome c release was observed in both MDA-MB-435 and MCF-7 cells 
after -T treatment. All of aforementioned data support the involvement of intrinsic 







Figure 4.5. γ-T induced mitochondria dependent apoptosis. A, MDA-MB-435 
cells were treated with 40 μM of γ-T for indicated time points and analyzed by 
western blot assays. B, Mitochondrial potential was detected using JC-1 labeling 
and FACS analyses after MDA-MB-435 cells were treated with 40 μM of γ-T. 
Decrease of mitochondrial potential was observed by the increase of cell 
population with loss of red and gain of green fluorescence. C, Release of 
cytochrome c from mitochondria was determined by indirect immunolabeling 
followed by FACS analyses. Numbers in graph represent percentage of cells 
without intact cytochrome C in mitochondria. All data were repeated twice. Data 



































4.3.6. -T significantly suppressed tumor growth in nude mice xenografted with 
MDA-MB-231-GFP human breast cancer cells. 
Anticancer effects of dietary -T (500 mg of -T/kg diet) was tested in nude mice bearing 
tumors of MDA-MB-231-GFP human breast cancer cells. For comparison, basal diet 
(containing 33 IU all-rac--T acetate), -T diet (500 mg of -T/kg diet, equivalent to 
400 IU/day/human) or -T+-T (500 mg each compound/kg diet) were also tested. As 
shown in Figure 4.6.A, dietary -T significantly attenuated tumor growth while dietary -
T did not, suggesting -T, but not -T exhibits antitumor activity, which were also 
correlated with in vitro cell culture studies. Interestingly, tumor suppressive effect of -T 
was blocked when co-administered with -T, suggesting that -T inhibits antitumor 
activity of -T as measured by reduction in tumor burden. Immunohistochemical analyses 
of tumor sections using TUNEL or Ki-67 labeling showed that dietary delivery of -T 
increased the number of TUNEL positive cells (P=0.03) and reduced the number of Ki-
67 positive cells (P=0.06) in tumors; whereas -T or -T+-T diet groups exhibited no 
difference from the control diet group (Figure 4.6.B & C). These data verify that -T 









Figure 4.6. γ-T suppressed tumor growth by inducing apoptosis and 
inhibiting cell proliferation. A, Each supplemental diet was provided from Day 
0 when MDA-MB-231-GFP tumors were palpable (approximately 25 mm
3
). 
Tumor volumes were determined every 2 days. Data are depicted as meanSE 
(n=10). *Significant difference from control diet group (P<0.05). B & C, 
Apoptotic cells (TUNEL positive, B) or proliferation cells (Ki-67 positive, C) in 
tumor section were assessed by immunohistochemical analyses. Data are  





















































































Table 3. Serum levels of -T and γ-T (adopted and modified from 
Yu et al. (18)). 
 
a 
Blood was collected at euthanasia, and the serum was 
harvested after blood clotted. Lipids were extracted, and levels 
of -T and  -T were analyzed by HPLC. Data are depicted as 
meanS.E. (n=5). 
b 
-T levels reflect all steroisomer forms 
 
c 
ND = not detected (below detection levels)  
 
 
4.3.7. -T concentration in the serum was reduced by co-administration with -T. 
Levels of -T and -T in mice sera were analyzed by HPLC analyses as shown in Table 
4.1. Serum levels of -T increased after dietary supplementation of -T or -T+-T in 
comparison to the control diet. In the case of the -T supplementation group, serum levels 
of -T were decreased but no statistical difference was observed. Serum levels of -T 
were detected after -T supplementation (1.3  0.2 mol/L) which was retained 
approximately 10 times lower than -T levels after same amount of -T supplementation. 
Serum levels a (mol/L)
Group -T b -T
Control 8.5  1.3 ND c
-T 14.2  1.7 ND
-T 5.7  0.4 1.3  0.2
-T +-T 12.5  1.7 ND
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These data indicate superior stability of -T in the serum. Notably, -T was not detected 
in the serum after -T + -T supplementation.  
 
4.3.8. -T concentration in tissues was enhanced by co-administration of -T with 
sesamin.  
Next, we tested if co-treatment of sesamin, a natural product CYP3A inhibitor extracted 
from sesame oil, with -T in the diet enhanced the metabolic stability of -T. MCF-7-GFP 
tumor bearing nude mice were fed -T (250 mg/kg diet) or -T+sesamin (250 mg of -T + 
1.3 g of sesamin/kg diet) supplemented diets for 40 days. HPLC analyses of -T 
concentration in serum, tumor and liver are shown in Figure 4.7. Although the serum 
concentration of -T was slightly enhanced by the combination treatment of -T +sesamin 
in comparison to -T supplementation alone, no significant difference was observed 
(P=0.29, n=5). On the other hand, -T retention in liver and tumor was enhanced 
approximately 2-fold in the -T +sesamin supplemented group compared to -T alone 
[P=0.005 (n=5) and P=0.07 (n=3 or 4), respectively]. These results suggest that sesamin 









Figure 4.7. Sesamin enhanced concentration of γ-T in liver and tumor.  Each 
supplemental diet was provided from Day 0 when MCF-7-GFP tumors were 
palpable (approximately 25 mm
3
). On Day 40, serum (A), liver (B) or tumor (C) 
were collected and tissue concentration of -T was determined by an internal 
standard method using reverse-phase HPLC with fluorometric detection. Data are 




-T is the most abundant form of vitamin E in the western diet and recent research reports 
about its potential anticancer properties in colon and prostate cancer highlight its 
potential for benefiting human health. However, much remains unclear regarding 
mechanisms of anticancer properties of -T and interactions among the different forms of 
vitamin E found in the diet. Here, we investigated the possible application of -T as an 
























































































as well as in the animal xenograft tumor models. Data presented here showed that: 1) -T 
induced apoptosis in human breast cancer cells but not in normal epithelial cells; 2)  
TRAIL resistant breast cancer cells became sensitive to TRAIL-induced apoptosis after 
pre- or combination treatments with -T; 3) -T increased the expression of DR5 mRNA, 
protein, and cell surface expression levels; 4) knockdown of DR5 or FADD attenuated -
T‟s apoptogenic activity as well as the ability of -T to sensitize TRAIL-resistant tumor 
cells; 5) -T induced mitochondria-mediated apoptosis in human breast cancer cells; 6) -
T attenuated tumor growth in nude mice bearing MDA-MB-231 human breast cancer 
cells and -T antagonized the antitumor effect of -T; and 7) tissue concentrations of -T 
were increased by co-treatment with sesamin, a natural product CYP3A inhibitor.  
Previous studies in our lab showed that tocopherols do not induce apoptosis in human 
breast cancer cells under regular cell culture conditions (91).  Here, we modified cell 
treatment conditions by reducing cell density in culture as previously proposed by Jiang 
et al. (14). This modification resulted in human breast cancer cells being induced to 
undergo apoptosis by -T but not by -T. The proapoptotic property of -T has been 
confirmed in other types of human cancer cells (15, 127); however the mechanisms 
involved in -T triggered apoptosis have not been well defined. In prostate cancer cells, -
T induced apoptosis via both caspase-dependent and –independent mechanisms (127) and 
also interrupts sphingolipid synthesis, an effect which is critical to cell death induction 
(14). Studies presented here demonstrate that -T triggers apoptosis in human breast 
cancer cells via activation of DR5 which is critical for -T-induced apoptosis as well as 
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for sensitization of breast cancer cells to TRAIL-induced apoptosis.  Additionally, DR5 is 
up-regulated by -T at mRNA, protein and cellular membrane levels. Transcriptional 
regulation of DR5 has been proposed to be regulated by multiple factors including JNK, 
p53, NF-B, and Myc (128-131). Increased levels of phosphorylated JNK and c-Jun have 
been observed after -T treatment of human breast cancer cells (unpublished data), 
suggesting JNK may be involved in transcriptional activation of DR5 by -T. Ongoing 
studies will determine if JNK/c-Jun mediates -T induced apoptosis and also if there is a 
coupling of -T mediated endoplasmic reticulum stress with JNK/c-Jun activation.  
Activation of DR5 by -T seems to play a major role in restoring sensitivity to TRAIL-
induced apoptosis in TRAIL-resistance cells. Agents that can increase the expression of 
TRAIL receptors, namely DR4 and/or DR5 have potential for clinical application in 
combination with TRAIL to enhance therapeutic potential of TRAIL. These agents 
include radiation, chemotherapeutic drugs, and natural products (108, 126, 132, 133); 
however, some of these agents also produce significant systemic toxicity. Therefore, it is 
of interest to study if -T can effectively sensitize cancers to TRAIL-induced apoptosis 
without any systemic toxicity in animal tumor models.  
Based on knockdown studies of DR5 and FADD, the cleavage of caspase 8 observed 
after -T treatment is highly likely to be caused by activation of DR5 signaling. In a 
manner distinct from the type I mitochondria-independent apoptotic signaling pathway in 
which high levels of activated caspase 8 directly activate caspase 3, -T-mediated 
activation of DR5 involves caspase-8 activation followed by mitochondria-dependent 
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apoptotic signaling (type II) in which involves DISC formation via adaptor protein, 
FADD (134). This conclusion is supported by data presented in our studies showing 
increased levels of truncated Bid, active Bax, cytochrome C releases from mitochondria; 
decreased mitochondrial membrane potential; and increased caspase 9 cleavage. 
Next, we evaluated the antitumor potential of dietary -T in comparison to -T in nude 
mice xenografted with MDA-MB-231-GFP human breast cancer cells. This study 
confirmed our previously reported study showing oral gavage of liposomal formulated -
T suppressed 66cl-4-GFP mouse mammary tumor growth in a syngeneic model (17).  In 
both the xenograft and syngeneic tumor models, -T, but not -T, attenuated tumor 
growth when administered by either oral gavage or dietary supplementation. Although -
T is the most abundant form of vitamin E in the US diet, -T is the predominant form of 
vitamin E detected in human serum (135). This difference in bioavailability can be 
explained by the superior affinity of -T to the -tocopherol transfer protein (-TTP) 
that is expressed in the liver and responsible for preferential release of -T from liver into 
the serum. The other vitamin E compounds, including -T, have lower binding affinity to 
TTP and are excreted into bile or metabolized in the liver (7). In addition to preferential 
binding of -T to -TTP, -T is known to activate P450 enzymes that degrade and 
eliminate other forms of vitamin E, which also accounts for the preferential presence of 
-T in serum and tissues (8, 136). Consistent with previously reported studies that 
demonstrated antagonistic effect of -T on serum and tissue levels of -T, data presented 
here showed that antitumor effects of -T were negated by co-treatment with -T and so 
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was the serum level of -T. Therefore, reduced bioavailability of -T by co-
supplementation with -T is one possible mechanism whereby -T can antagonize -T 
antitumor action.  
Sesamin is one of the major components of sesame seeds which have high nutritional 
value (137). It has been proposed that sesamin modifies metabolism of tocopherols; for 
example, -T level in plasma and liver of rats is increased by combination 
supplementation of sesamin plus -T in comparison to single supplementation with -T 
(138). Mechanistic studies showed that the activity of CYP3A, the major P450 family 
member known to metabolize vitamin E compounds in human liver is inhibited by 
sesamin. Thus, sesamin prevents catabolism of tocopherols thereby permitting increased 
retention of tocopherols in serum and tissues (139). Our data are in agreement, showing 
that sesamin in combination with -T increased tumor and liver concentrations of -T.  
Yamada et al. (140) showed that dietary tocotrienols protect UVB-induced skin damage 
and this protective effect by tocotrienols is enhanced by cotreatment with sesamin due to 
increased distribution of tocotrienols in the skin. Therefore, it is of interest to investigate 
the use of sesamin to augment anticancer actions of -T.  
In summary, we investigated anticancer properties of -T in human breast cancer cells 
and a xenografted human breast cancer animal model. Mechanistic studies showed that -
T triggered extrinsic death receptor mediated apoptosis signaling by increasing DR5 
mRNA, protein and cell surface expression levels followed by mitochondria-dependent 
apoptotic signaling. -T suppressed MDA-MB-231-GFP tumor growth in nude mice but 
121 
 
the antitumor activity of -T was hampered by coadministration of -T. The preferential 
tissue retention of -T over -T could be overcome by co-administration with sesamin, 




Chapter 5. Conclusion and future directions 
5.1. Conclusion 
Studies in this dissertation investigated possible application of various forms of natural-
source vitamin E and novel derivatives as therapeutic agents to fight breast cancer. To 
date, -TEA, a redox-silent derivative of -T, has served as the best example of a 
vitamin E-based anticancer agent capable of inducing apoptosis selectively in cancerous 
cells but not in normal cells.  Based on the concept of modifying antioxidant molecule to 
generate apoptogenic, cancer targeting agents, we chemically modified tocotrienols, 
potent apoptogenic natural source vitamin E forms, to redox-silent derivatives; namely, 
-T3EA and -T3EA. These novel compounds displayed improved apoptosis-inducing 
abilities and antiangiogenic activities in comparison to the parent compounds or -TEA 
in cell culture studies.  Although -T3EA showed an improved tumor suppressive effect 
compared to -T3 in a syngeneic mouse tumor model, no major differences in tumor 
suppressive effects were observed between the novel tocotrienols (-T3EA or -T3EA) 
in comparison to either -TEA or -T3. These data suggest that these redox-silencing 
modifications to the chroman head of the tocotrienol structure are not sufficient to 
dramatically augment anticancer efficacy in vivo, regardless of various improvements in 
anticancer and antiangiogenic properties observed in cell culture studies. One possible 
explanation of limited in vivo efficacy of the novel tocotrienol derivatives is the low 
bioavailability achieved as observed in the low liver concentration of -T3EA which may 
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result in ineffective tumor suppressive effects. Therefore, next generation of vitamin E 
derivatives should involve profound modifications of the chroman head or the tail of 
vitamin E structure to enhance metabolic stability in the liver, so that significant tissue 
retention and anticancer activities can be achieved.   
Some natural-source vitamin E forms, especially -forms, were studied to better 
understand their mechanism of apoptogenic actions on human breast cancer cells. Data 
presented here demonstrated that both -T3 and -T trigger apoptosis via up-regulation of 
DR5 which induces caspase-8, -9 and -3 mediated apoptotic signaling events. Increase of 
DR5 by -T3 is mediated by endoplasmic reticulum (ER) stress which is coupled with 
JNK and p38MAPK activations followed by increase of the transcription factor CHOP 
which can directly bind to the promoter region of DR5 and activate DR5 gene expression. 
Phosphorylation of JNK was also observed in -T-induced apoptosis, but it is still unclear 
if JNK activation by -T treatment is coupled with ER-stress. In preclinical animal 
models, dietary delivery of -T3 and -T significantly attenuated the growth of tumors by 
inducing apoptosis and cell growth inhibition. However, anti-tumorigenic activity of -T 
was blocked by co-administration of -T, which is in agreement with previous studies 
showing antagonistic effects of -T on the serum and tissue levels of -T. Therefore, in 
order to utilize vitamin E forms demonstrating potent anticancer activity as a promising 
approach to target cancer, novel delivery methods designed to evade liver metabolism or 
124 
 
combination supplementation with agents known to inhibit metabolic enzymes need to be 
implemented to increase stability of these compounds.  
 
5.2. Future directions 
Previous studies testing different forms of natural-source vitamin E compounds in 
various types of cancer cells consistently have shown that -forms of vitamin E 
compounds have the least, -forms have a better, and -forms have the best apoptogenic 
properties. Unfortunately, their bioavailability is known to be inversely proportional to 
their anticancer activities (Figure 5.1).  
 
Figure 5.1. Correlation of structure, anticancer activity, and bioavailability 
of natural vitamin E forms.  
 
The correlation between number of chroman head methyl groups with anticancer efficacy 




























to increase electronegativity on the phenolic ring and decrease the molecular size of the 
chroman head, suggesting that a vitamin E derivative with high electronegativity and low 
steric effect on the chroman head plus increased metabolic stability would be predicted to 
display improved anticancer properties in both in vitro cell culture and in vivo animal 
models.  
Fluorine (F) is a small element with high electronegativity (141). Carbon-bound fluorine 
(C-F) often replaces carbon-bound hydrogen (C-H) in drug design strategies since F is 
the smallest atom that can replace H (142). Recent examination of structure-activity 
relationships during drug discovery and the lead compound optimization have shown that 
fluorinated compounds have advantageous properties in the design of small molecules. 
For example, introduction of fluorine atoms can increase metabolic stability of a 
compound by lowering the susceptibility of nearby moieties to P450 enzymatic oxidation; 
replacing H with F can lead to a change in the molecular conformation which may be 
preferable; and fluorinated compounds can have a significant increase on binding affinity 
of protein-ligand complexes either directly or indirectly (141, 143). In this regard, 
introducing fluorine into the design of new vitamin E derivatives may overcome 
insufficient bioavailability of some types of vitamin E compounds. As shown in Figure 
5.2, several fluorinated vitamin E derivatives have been synthesized. Based on 
preliminary cell culture studies, compounds that contain a single fluorination and no 
methyl groups on the chroman head (new compounds #2 and 7 in Figure 5.2) exhibited 
improved apoptogenic activity in comparison to -TEA (Figure 5.3). Another 
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modification that influenced the apoptogenic potential was the addition of an ether 
linkage between the chroman head and phytyl tail (new compounds #4, 5 and 7 in Figure 
5.2). More comprehensive cell culture studies will need to be performed to explain the 
mechanistic aspect of these structural modifications. Anticancer efficacy studies in valid 
animal tumor models in conjunction with bioavailability analyses are anticipated. 
  
 
Figure 5.2. Structures and molecular weights of novel fluorinated vitamin E-
related compounds and novel derivatives of -TEA with either an S- or R- 


















































New #1 (Mw. 406.62)
New #2 (Mw. 464.65)
New #4 (Mw. 504.74): (S) form
New #5 (Mw. 504.74): (R) form
New #6 (Mw. 422.32)





Figure 5.3. Anticancer activities of novel vitamin-E based compounds in 
mouse mammary tumor cells and human breast cancer cells. A, Cells were 
treated with 20 M of each compound for 16 hours. Control cells were treated 
with the vehicle (final concentration of 0.05% ethanol). Cells were collected and 
PARP cleavage (indicated by arrow) were analyzed using western blot assay. 
Data are representative of two independent assays. B, Cells were seeded in 12-
well plates at 300 cells for 66cl-4 and MCF-7 cells and 200 cells for MDA-MB-
231 cells. After 48 hours, cells were treated with each compound as indicated 
concentrations for 2 weeks. Control cells were treated with the vehicle (final 
concentration of 0.02% ethanol). After 2 weeks, cells were fixed with 10% 
formalin followed by staining with 2% (w/v) crystal violet in H2O. Colonies 
containing more than 50 cells were scored. Colony formation data are depicted as 
percentage of control (meanSD, n=2-3).  
-TEA
MCF-7
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Appendix 1. Anti-metastatic effect of novel vitamin E-related analogs   
Fluorinated vitamin E-based compounds and novel -TEA derivatives were synthesized 
and tumor-suppressive and anti-metastatic activities of these compounds were tested in a 
syngeneic mouse mammary tumor model using highly metastatic 66cl-4-GFP cells.  
A1.1. Materials and methods 
A1.1.1. Chemical reagent 
Novel vitamin E-related analogs (#2, 4, 5 and 7; Figure 5.2) were chemically synthesized 
by Dr. Wenbin Chen.   
A1.1.2. Animal study 
The animal study was conducted in accordance with “Guidelines for the humane 
treatment of animals” as designated by the University of Texas Institutional Animal Care 
and Use Committee. Female BALB/c mice at 4-6 weeks of age were purchased from 
Jackson Laboratories (Bar Harbor, ME). The source and culture conditions for 66cl-4-
GFP murine mammary tumor cells were previously described (1). 66cl-4-GFP cells were 
harvested and resuspended at a density of 2 x 10
5
 cells/100 µl cell medium without any 
serum or antibiotics. Mice were injected subcutaneously with 2X10
5
 cells in the inguinal 
area at a point equal distant between the fourth and fifth nipples on the right side. Tumor 
size was measured using calipers and calculated according to the equation V= (X
2
Y)/2, 
where V is the volume of each tumor, X is the smaller diameter, and Y is the larger one 
(1). When tumors reached an average volume of 10.7 mm
3 
(day 13 after tumor cell 
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injection), mice were randomly assigned to 6 groups (7 or 8 animals/group): Control 
(vehicle control), -TEA, #2, #4, #5 and #7. Animals were sacrificed on day 15 after 
treatments and tumor, heart, lung, spleen, liver and kidney were collected for measuring 
organ weights.   
A1.1.3. Liposomal formulation and intraperitoneal (IP) injection 
Each compound was formulated in liposome and lyophilized as described by Lawson et 
al (2). A dry powder of each compound was stored at -20 C until the day of injection. 
Each treatment vial contained 6 to 6.25 mg of the compound. On treatment day, each vial 
was first brought to room temperature and the compound was dissolved in filter-sterilized 
water at a concentration of 3 mg/mL.  Animals in each group received liposome (control) 
or 0.4 mg of each compound (in 130 L) by IP injections every 4th day (on day 1, 5, 9 
and 13).   
A1.1.4. Determination of lung metastases 
Visible lung metastases were counted after fixation in Bouin’s solution as described by 
Giavazzi and Garofalo (3).  
A1.1.5. Statistical analysis 
Differences in number of treated versus control visible lung metastases and tumor/organ 
weights were determined by t-test using Prism software version 4.0 (Graphpad, San 




A1.2.1. Intraperitoneal delivery of vitamin E-related compounds had no effect on 
tumor growth in vivo 
In previous cell culture studies, novel vitamin E-related compounds showed markedly 
improved apoptogenic activities and colony formation inhibitory effects in both murine 
mammary and human breast cancer cells (Figure 5.3). Here, we tested the anti-tumor 
efficacy of each compound in comparison to -TEA in the 66cl-4-GFP syngeneic mouse 
mammary tumor transplantation model. To find the optimal dose for IP treatment, -TEA 
was formulated in liposomes at various concentrations (1, 2, 4, 5, 10, and 20 mg/mL) and 
tested using the same animal model (n=4). Total 5 IP injections of 0.4 mg -TEA per 
mouse every 4th day attenuated tumor growth by 40% in comparison to the vehicle 
control group (data not shown). Body weight losses of 16 and 21% in 2 out of 4 mice 
after the first injection were observed until day 5 after treatment initiation, but the body 
weights in these 2 mice recovered on day 7 after treatment initiation and remained 
consistent until the termination of the experiment (data not shown). Based on this pilot 
study, each compound was formulated in liposome and delivered by IP injection at the 
dose of 0.4 mg/mouse (n=7 or 8/group) every 4th day. As shown in Figure A1.1, no 
tumor inhibitor effect was observed in any treatments, which suggests that either the dose 
of each compound was not high enough or IP injection is not the best route to deliver 
vitamin E-related compounds to study anti-tumor activity in vivo. Slight weight loss was 
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observed after the 2nd injection of -TEA and compound #7; however it was recovered 
after 2 days. No body weight differences was observed between treatments with each 
compound.  
A1.2.2. Novel vitamin E-related compounds inhibited lung metastases in vivo 
Visible lung metastases were counted after fixation in Bouin’s solution. A reduction in 
the incidence of lung metastases was observed in #2 treated group compared to the 
control group (Table A1). Also, IP treatment of compound #5 reduced the average 
number of visible lung metastases observed in the metastases bearing animals compared 
to the vehicle treatment (Table A1). In agreement with these data, average lung weight of 
#2 and #5 treated groups were measured less than the control group (Figure A1.2), 
suggesting that compounds #2 and #5 suppressed lung metastases in vivo. No difference 
of the average organ weight between each treatment was observed except that the average 
kidney weight of compound #7 group was significantly reduced from the control group 











Figure A1.1. Average tumor volume (meanSE) over time of BALB/c mice 
bearing 66cl-4-GFP tumor cells. Each compound was formulated in liposome 
and mice received liposome (control) or 0.4 mg of each compound by IP 
injections () every 4th day. Tumor volume was measured every other day as 






































Table A1. Visible lung metastases in BALB/c mice receiving each compound 
formulated in liposome 
 
a
 Visible lung metastases in all five lung lobes in each animal were counted after 
fixation in Bouin’s solution. 
b
 Data are depicted as the mean  SE of visible lung metastases observed in the 
animals bearing lung metastases.   
c 
Significantly different from the control (P=0.042, t-test). 
  
Treatment groups
Number of animals with visible 
lung metastases/total animal
number in a group a
Average number of visible 
lung metastases/animal b
Control 7/8 2.43  0.37 (n=7)
-TEA 6/7 2.83  0.60 (n=6)
#2 4/8 3.25  1.11 (n=4)
#4 7/8 2.86  0.51 (n=7)
#5 5/7 1.40  0.24 (n=5) c







Figure A1.2. Average organ weight (meanSE) of BALB/c mice. Each organ was 
collected at the time of animal sacrifice on day 15 after each treatment.  
a 
Significantly 
different from the control (P<0.05, t-test, n=7 or 8); 
b 
Marginally different from the 


























































































Our goal was to generate stronger vitamin E-related anticancer therapeutics with 
enhanced metabolic stability. Toward this goal, we incorporated fluorine at the chroman 
head and/or ether linkage between chroman head and phytyl tail of -TEA and tested 
newly synthesized vitamin E-related compounds for their anticancer effects using a 66cl-
4-GFP syngeneic mouse mammary tumor transplantation model. Data presented here 
demonstrated that: 1) intraperitoneal delivery of vitamin E-related compounds at 0.4 mg 
per mouse every 4th day did not display tumor inhibitory activities in a ; 2) newly 
synthesized compound #2 reduced the incidence of visible lung metastases; and 3) newly 
synthesized compound #5 reduced average number of visible lung metastases.  
Due to limited amounts of newly synthesized compounds, we decided to deliver these 
compounds via liposomal formulations intraperitoneally. Although -TEA has shown 
consistent tumor inhibitory effects in previous animal studies when delivered orally (1, 2, 
4-9), intraperitoneal injections of 0.4 mg of -TEA in liposome per mouse up to four 
times did not suppressed tumor growth. Instead, 100% and 75% lethality was observed 
after one injection of 2 and 1 mg of liposomal formulated -TEA per mouse respectively, 
and severe weight loss (> 15% of body weight) was observed after one injection of 0.5 
mg of liposomal formulated -TEA per mouse in a preliminary dose response studies. 
These have never been observed when liposomal formulated or vesiculated -TEA was 
delivered via oral routes. This may suggest that intraperitoneal route is not a proper way 
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of testing novel vitamin-E related compounds formulated in liposomes as attempted here. 
Although no tumor inhibitory effects were observed from novel compounds treatments, 
compounds #2 and #5 exhibited marginal inhibitory effect on lung metastases. More 
comprehensive cell culture studies will need to be performed to explain the mechanistic 
aspect of these structural modifications. Anticancer efficacy studies in a valid animal 
tumor model with oral routes in conjunction with bioavailability analyses are also needed 
to characterize the anticancer potential of these novel agents. 
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Appendix 2. -TEA improves obesity-induced glucose intolerance and insulin 
insensitivity  
Obesity is highly associated with the development of various chronic diseases such as 
cardiovascular diseases, type 2 diabetes, hypertension, stroke, dyslipidemia and some 
cancers (1). One common feature of obesity-related complications is obesity-induced 
adipose tissue inflammation (2; 3) characterized by abnormal production of adipokines, 
free fatty acids (FFA), and proinflammatory cytokines including tumor necrosis factor- 
(TNF-), monocyte chemoattractant protein 1 (MCP-1), and interleukin 6 (IL-6) (4; 5).  
These proinflammatory signals involve intracellular signaling pathways, such as nuclear 
factor kappa light-chain enhancer of activated B cells (NF-B) system (4). Increased 
production of proinflammatory cytokines and FFA by adipose tissue contributes to 
macrophage infiltration into adipose tissue, thereby exacerbating chronic inflammation 
and eventually impairing insulin action in peripheral tissues, such as fat and skeletal 
muscle (6).  
-TEA, an R,R,R--tocopherol derivative possessing pleiotropic anticancer activities, has 
shown to modulate AMP-activated protein kinase (AMPK) activity, a sensor and 
regulator of cellular energy balance (unpublished data). Activation of AMPK is involved 
in glucose transport and fatty acid oxidation which result in improvement of glucose 
homeostasis and breakdown of stored fat (7). Studies using antidiabetic agents have 
shown that insulin-sensitizing action of these agents requires AMPK activation in 
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peripheral tissues (8). Notably, AMPK activation in macrophages can downregulate 
proinflammatory responses and also improve insulin sensitivity in adipocytes, suggesting 
that AMPK is a potential target for the treatment of inflammation associated disorders (9). 
Here, we investigated the possible application of -TEA for the prevention of obesity 
related complications using mouse macrophages and adipocytes in cell culture; as well as, 
dietary administration of -TEA in a diet-induced obese (DIO) mouse model.  
 
A2.1. Materials and methods 
A2.1.1. Cell culture and reagents 
Mouse macrophages (RAW264.7) and fibroblasts (3T3-L1) were purchased from the 
American Type Culture Collection (ATCC). RAW264.7 cells were cultured and 
maintained in Gibco RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented 
with 10% (v/v) fetal bovine serum (HyClone, Logan, UT), 100 g/mL streptomycin, and 
100 units/mL penicillin. 3T3-L1 cells were cultured and maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) high glucose medium (Invitrogen) supplemented 
with 10% (v/v) bovine calf serum (Gemini Bio-Products, West Sacramento, CA), 100 
g/mL streptomycin, and 100 units/mL penicillin following manufacturer’s instructions. 
Curcumin (C1386), dexamethasone (DEX, D4902), 3-isobutyl-1-methyl-xanthine (IBMX, 
I7018) and insulin (INS, I6634) were purchased from Sigma-Aldrich (St. Louis, MO). 
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Recombinant mouse tumor necrosis factor- (TNF-) was purchased from R&D Systems 
(Minneapolis, MN).  
A.2.1.2. Cell viability assay (MTS assay) 
Effect of -TEA on cell proliferation was assessed in RAW264.7 macrophages in cell 
culture. Cells at 5X10
3
/well were seeded in 96-well plates. Cells were treated with a 
range of concentrations of -TEA (1.25 to 40 M). Control cells were treated with the 
vehicle (ethanol) at a final concentration of 0.1 %. After 48 hrs, viable cells were 
measured using CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit 
(Promega, Corp., Madison, WI) following manufacturer’s instructions. The percentage of 
viable cells at each concentration was calculated by dividing color absorbance (A290) of 
treated cells by that of control cells.   
A.2.1.3. 3T3-L1 adipocyte differentiation and TNF- treatment 
To differentiate 3T3-L1 fibroblasts into adipocytes, 4 days post-confluent 3T3-L1 cells 
were treated with 10 /mL INS, 1 M DEX and 0.5 mM IBMX for 72 hrs. Cells were 
maintained in adipocyte maturation medium containing 10 g/mL INS in complete 
medium. Media were changed every 2-3 days (10). To induce inflammatory cytokine 
genes, differentiated adipocytes (Day 6 after differentiation) were treated with TNF- (20 




A.2.1.4. Western blot analyses 
Whole cell lysates were used to analyze protein expression levels as previously described 
(12). Antibodies to poly (ADP-ribose) polymerase (PARP) and NF-B p65 were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to inhibitor of 
NF-B (IB)-, AMPK, phospho-AMPK (p-AMPK) , and phosphor-acetyl-CoA 
carboxylase (p-ACC) were purchased from Cell Signaling Technology (Beverly, MA). 
Secondary antibodies conjugated with horseradish peroxidase included goat anti-rabbit 
and rabbit-anti-mouse IgG (Jackson Immuoresearch, Rockford, IL).   
A.2.1.5. Quantitative real time-PCR (qRT-PCR) analyses of inflammatory cytokines 
Changes in messenger RNA levels for inflammatory cytokines in 3T3-L1 adipocytes 
after TNF- treatment were assessed. Cells were differentiated for 6 days and treated 
with TNF-  in combination with 0.01% ethanol or 20 and 40M -TEA for 48 hrs. 
Cells were then collected and total RNA was purified using RNeasy mini kit following 
manufacturer’s instructions (Qiagen Inc. Valencia, CA). Two g of RNA from each 
sample was used for the reverse transcription reaction using SuperScript First Strand 
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA). Quantitative analyses of each 
gene using specific primers (Table A2) were performed with 1 L cDNA using SYBR 
Green PCR Master Mix (Applied Biosystems Inc., Forster City, CA) following 
manufacturer’s instructions. Each primer set was used at a concentration of 2 M in a 
final reaction volume of 20 L. Changes in gene expression were analyzed by 
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comparative CT method following ABI PRISM 7700 Sequence Detection System User 
Bulletin #2: Relative Quantitation of Gene Expression (P/N4304859). The 36B4 gene 
(ribosomal acid phosphoprotein P0) was used for internal control to normalize target gene 
expression (13). 





(5’  3’) 
References 
COX-2 TGGGGTGATGAGCAACTATT AAGGAGCTCTGGGTCAAACT (14) 
MCP-1 GCCCACTCACCTGCTGCTACT CCTTGCTCGTCCTCATCCTCTTGT (15) 
IL-6 AGTTGCCTTCTTGGGACTGA CAGAATTGCCATTGCACAAC (14) 
36B4 GGCCCTGCACTCTCGCTTTC TGCCAGGACGCGCTTGT (13) 
 
A2.1.6. Diet-induced obese (DIO) mouse model 
The animal study was conducted in accordance with “Guidelines for the humane 
treatment of animals” as designated by the University of Texas Institutional Animal Care 
and Use Committee. Female C57BL/6 mice at 4-6 weeks of age were purchased from 
Jackson Laboratories (Bar Harbor, ME). Mice were acclimated for 10 days and randomly 
divided into 5 groups (10 animals/group). Each group received corresponding diet for 91 
days and all diets were purchased from Research Diets (New Brunswick, NJ). Group 1 
received rodent lean control diet (10% total kcal% from fat, D12450B), group 2  received 
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high fat diet (60% total kcal% from fat, Diet D12492), group 3  received high fat diet 
containing -TEA (Diet D12492+500 mg alpha-TEA/kg diet), group 4 received high fat 
diet containing curcumin (Diet D12492+500 mg curcumin/kg diet), and group 5 received 
high fat diet containing both curcumin and -TEA (Diet D12492+500 mg curcumin and 
500 mg alpha-TEA/kg diet).  Body weights and food intake were monitored every 3-4 
days. The fat tissue mass was determined using quantitative magnetic resonance (Echo 
Medical Systems, Houston, TX) on Days 34, 69 and 89.  
A2.1.7. Glucose tolerance and insulin sensitivity tests  
On day 80, tail-tip blood was collected to measure fasting glucose level of overnight 
(approximately 16 hrs) fasted-animals using Accu-Chek Compact Plus glucometer 
(Roche, Basel, Switzerland). Then to determine glucose tolerace, mice were injected with 
20% glucose intraperitoneally (2 g/kg) and thereafter the blood glucose levels were 
measured at 15, 30, 60 and 120 min. As an indication of insulin sensitivity, the 
homeostasis model assessment (HOMA) was used as described by Hong et al. (16).  
Briefly, on the day of animal sacrifice (Day 91), overnight fasting glucose level was 
measured as described above. Blood was collected from heart puncture after CO2 
asphyxiation. Serum insulin was measured using Insulin (mouse) Ultrasensitive ELISA 
kit (ALPCO, Salen, NH) following manufacturer’s instructions. HOMA-IR values were 
calculated using the formula below:  
   A I   
fasting insulin  
g
m    fasting glucose  
mmol
      




A2.1.8. Statistical analyses 
Differences in in vitro gene expression, body weight, fat mass, glucose tolerance test, 
HOMA, and organ weights were determined with t-test. A level of P<0.05 was regarded 
as statistically significant.   
 
A2.2. Results 
A2.2.1. -TEA reduced NK-B expression and induced apoptosis in RAW264.2 
mouse macrophages  
Effects of -TEA on inflammation were tested using RAW264.2 mouse macrophages. 
Treatment of -TEA inhibited macrophage cell viability and also induced apoptosis 
based on PARP cleavages in a dose dependent manner (Figure A2.1.A & B). Decreased 
expression of NF-B p65 was also observed by -TEA treatment (Figure A2.1.B).  
A2.2.2. -TEA induced AMPK activation and reduced inflammatory factors in 
TNF--activated adipocytes.   
Next, -TEA effects on AMPK signaling were tested in 3T3-L1 adipocytes. As shown in 
Figure A2.2.A, phosphorylation of AMPK as well as ACC, a target of AMPK, was 
increased by -TEA treatment, suggesting that AMPK is activated by -TEA in 
adipocytes. In addition, NF-B p65 protein level was decreased while IB protein level 
145 
 
was increased in 3T3-L1 adipocytes following -TEA treatment. To further determine 
the role of -TEA in inflammation, TNF- was added to the 3T3-L1 adipocytes to 
trigger inflammatory signaling. As shown in Figure A2.2.B, C & D, addition of TNF- 
markedly increased mRNA levels of IL-6, COX-2 and MCP-1, whereas co-treatment with 
TNF-+-TEA significantly suppressed the gene activation of these inflammatory 




Figure A2.1. -TEA inhibited cell proliferation (A) and induced apoptosis in 
RAW264.7 macrophages (B). A, Cells were treated with 1.25, 2.5, 5, 10, 20 and 
40 M -TEA for 48 hrs and the cell viability was measured as described in 
A2.2. Materials and methods. Data are depicted as meanSD of triplicate plates. 
B, Cells were treated with indicated concentration of -TEA for 24 hrs and 
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Figure A2.2. -TEA activates AMPK pathway, downregulates NK-B expression, as 
well as suppresses inflammatory factor expression after TNF- stimulation. A, 3T3-
L1 cells were induced to differentiate for 6 days in the presence or absence (vehicle, 0.01% 
ethanol) of -TEA at indicated concentrations. Cell lysates were used for western blot 
analyses. B, C, & D, 3T3-L1 cells were induced to differentiate into adipocytes for 6 days, 
and then treated with 20 ng/mL TNF- in combination with 0.01% ethanol or 20 and 40 
M -TEA for 48 hrs. Cells were collected and analyzed to detect the expression of IL-6, 
COX-2, and MCP-1 by qRT-PCR using comparative CT method. Graphs in B, C & D 
represent percentage of gene expression in comparison to TNF- single treatment.  Data 
represent two or three independent experiments (meanSD). *Statistically different from 















































































































































A2.2.3. -TEA did not affect body weight or fat mass in diet-induced obese mice. 
Based on cell culture studies showing that -TEA suppressed NF-B expression and the 
mRNA expression of inflammatory cytokines in adipocytes, we hypothesized that -TEA 
will inhibit obesity-induced inflammation. To test this hypothesis, we used a diet-induce 
obese mouse (DIO) model. Female C57BL6 mice were fed a high-fat diet for 90 days 
with or without -TEA (500 mg/kg diet). Curcumin which has been shown to inhibit 
adipogenesis and body weight gain in the same animal model served as a positive control 
(17). As shown in Figure A2.3, -TEA did not affect weight gain or fat mass in DIO 
mice. Curcumin slightly decreased body weight and fat mass compared to the high fat-
diet fed control group, but no statistically significant differences were observed.  
 
Figure A2.3. Average body weight (A) and fat mass composition (B) of C57BL6 
female mice. Data represent meanSE (n=10) for each group: LD (lean control diet); HF 
(high fat diet); HF+ (high fat diet + 500 mg -TEA/kg diet); HF+Cur (high fat diet + 
500 mg curcumin/kg diet); and HF Combo (high fat diet + 500 mg -TEA + 500 mg 
curcmumin/kg diet). 
a 
Significant difference from the high fat diet group (P<0.05, t-test).  




















































A2.2.4. -TEA improved obesity-associated glycemic status and insulin sensitivity in 
the DIO model.  
We determined if 500 ppm -TEA in diet could improve glycemic status in DIO mice. 
On day 80, mice received a glucose tolerance test for evaluating glycemic status. As 
shown in Figure A2.4.A & B, all treatments including -TEA, curcumin and combination 
of -TEA+curcumin significantly improved glucose tolerance in C56BL6 DIO mice. 
Improved insulin sensitivity was only demonstrated in -TEA group by HOMA-IR value 
but not in the other groups; however, no statistically significant difference was observed 








Figure A2.4. Effects of -TEA on glucose tolerance and insulin sensitivity in DIO 
mice. A & B, On day 80 after feeding designated diets, mice were fasted overnight and 
injected with 20% glucose intraperitoneally (2 g/kg). Thereafter, the blood glucose levels 
were measured at indicated time points (A). The area under the curve from 0 to 120 min 
(mg/dL X min) was calculated for each group (B). Data represent meanSE (n=10). 
a
 
Significant difference from all groups except HF+Combo (P<0.05, t-test); 
b
 Significant 
difference from all groups (P<0.05, t-test); 
c
 Significant difference from HF group 
(P<0.05, t-test); and 
d
 Significant difference from HF group (P=0.0512, t-test). C, D & E, 
On day 91, mice were sacrificed after overnight fasting and the blood was collected and 
measured for glucose level and serum insulin level. HOMA-IR was calculated as 











































































































































Our goal was to examine the possibility that -TEA, a chemopreventive agent that can 
activate AMPK might impact obesity related disorders. Toward this goal, we tested -
TEA effects on mouse macrophages and adipocytes in cell culture; as well as in a diet-
induced obese (DIO) mouse model. Data presented here demonstrated that: 1) -TEA 
inhibited proliferation, induced apoptosis and reduced NF-B expression in RAW264.7 
murine macrophages in cell culture; 2) -TEA caused activation of AMPK, decreased 
NF-B expression and increased IB expression in 3T3-L1 adipocytes in cell culture; and 
3) 500 ppm -TEA in diet did not affect body weight or fat mass; however, -TEA did 
improve glucose and insulin sensitivity in DIO mice.  
Although the mechanism(s) of how -TEA improved glycemic status in DIO animal is 
not clear, it is possible that -TEA prevents insulin resistance by inhibiting TNF- 
stimulation of proinflammatory signals based on cell culture studies using 3T3-L1 
adipocytes. Further tissue analyses from the DIO mouse study are needed to gain further 
mechanistic insights, and dose-dependent efficacy studies using DIO mice, ob/ob obese 
or db/db diabetic mouse models are also needed to confirm preventive or therapeutic 
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